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Abstract 
 
 
Background: Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer. 
The 5-year survival is about 30%, a consequence of failure to establish early 
diagnosis due to unspecific symptoms. The biomarker serum CA125 and 
transvaginal ultrasound are used as the “golden standards” for assessing ovarian cysts 
and pelvic tumors of unknown origin, but early diagnosis is still not achieved and 
specificity is low. Increased knowledge about EOC specific mutations has revised 
our understanding of ovarian cancer etiology and heterogeneity. Rare tumor 
mutations can be detected in liquid biopsies from different compartments. 
 
Aims: To investigate established EOC biomarkers and algorithms in an unselected 
population of women with ovarian cysts/pelvic tumors. To compare and combine 
established and new biomarkers and algorithms to improve differential diagnosis of 
EOC (paper I-III). To explore new ways for early detection of gynecologic cancer, 
from circulating tumor DNA (ctDNA) and somatic mutations, by mutation specific 
analysis in liquid biopsies from the genital tract and plasma (paper IV). 
 
Methods: A prospective multicenter trial (paper I-III) was conducted and we also 
participated in an international multicenter trial (paper IV) with the aim to improve 
diagnostic accuracy of EOC and to find new screening methods. Serum was collected 
for analysis of the biomarkers CA125 and HE4. Risk of Malignancy Index (RMI), 
Risk of Ovarian Malignancy Algorithm (ROMA) and new algorithms were explored. 
Patient and tumor characteristics were recorded at the time of inclusion and evaluated 
by multivariate regression analysis (paper I-III). Liquid biopsies were collected from 
genital tract thin-prep liquids and plasma. Corresponding formalin fixed and paraffin 
imbedded tissue biopsies were retrieved from the pathology repository. They were 
analyzed with a multiplex PCR based barcoding of DNA for mutation detection using 
next generation sequencing (PapSEEK) for rare mutations (paper IV).  
 
Results:  
Paper I: At the recommended cut-off level off >35, CA125 achieved highest 
sensitivity (SN) for both pre- and postmenopausal women (SN 95.7%; 92.0%), but 
low specificity (SP) in both pre- and postmenopausal women (Pre-M 59.6%; Post-M 
79.5%). HE4 was inferior compared to CA125 in SN but increased in diagnostic 
performance with the highest SP (Pre-M 90.9%; Post-M 92.1%). RMI and ROMA 
were identical in their predictive ability.  
Paper II: Three new algorithms were tested and found to perform better than RMI, 
ROMA or CA125 alone (GOT-1, GOT-2, GOT-3). The addition of HE4 to CA125 
or RMI increased SP without hampering SN.  
Paper III: Smoking, heart- or kidney failure and endometriosis should be considered 
when evaluating CA125 and HE4 levels in women assessed for an ovarian 
cyst/pelvic tumor of unknown origin.  
Paper IV: The PapSEEK technique showed impressively high SP (98.6% cervical; 
100% endometrial), and when cervical sampling was combined with plasma ctDNA 
analysis, SN for ovarian cancer was 63%, with retained SP of 100%.  
 
Conclusion: CA125 was superior to HE4 to identify women with ovarian cancer and 
HE4 was superior to CA125 to identify benign lesions, in this unselected population 
of women with an ovarian cyst/pelvic mass from the Western region of Sweden. 
Addition of HE4 to CA125 increased diagnostic accuracy and decreased false 
positives. Combining established and novel biomarkers and algorithms improved 
diagnostic accuracy of ovarian tumors. We suggest that HE4 should be incorporated 
for the differential diagnosis of women with ovarian cysts/pelvic tumors of unknown 
origin to decrease unnecessary oophorectomies. It is possible to detect somatic 
mutations and ctDNA from ovarian cancer in plasma, cervical- and endometrial 
liquid biopsies with high SP. This thesis demonstrate the potential of a protein and 
gene mutation-based diagnostic test to detect EOC. With improved technique, this 
might be a potential test for ovarian cancer screening, in the future. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sammanfattning på svenska 
 
 
Äggstockscancer eller epitelial äggstockscancer (EOC) är den mest dödliga 
gynekologiska cancerformen i världen. Den är svår att upptäcka eftersom sjukdomen 
föregås av ospecifika symtom såsom magsmärtor, mättnadskänsla och känsla av 
uppkördhet. Diagnosen ställs ofta i ett sent skede, då 5-årsöverlevnaden är mindre än 
30%. Med förbättrad diagnostik och möjlighet att ställa diagnos i stadium 1 förbättras 
5-årsöverlevnaden till nästan 90%. Biomarkören serum CA125 (CA125) och 
transvaginalt ultraljud (TVU) används som ”golden standard” vid bedömning av 
ovarialcystor/tumörer i lilla bäckenet av oklart ursprung men dessa metoder 
möjliggör inte att man hittar cancern tidigt. Genom att förbättra vår kunskap om 
ursprunget för cancern och den genetiska koden s.k. mutationer för olika typer av 
EOC, kan vi detektera tumörspecifika mutationer, via analyser från vätskebaserade 
prov från livmoderhals, livmoder slemhinnan eller cirkulerande tumör DNA 
(ctDNA) i blodet.  
 
Syftet med avhandlingen var dels att utvärdera etablerade EOC biomarkörer 
inklusive algoritmer eller kombinationer av dessa i en oselekterad population av 
kvinnor med en ovarialcysta/tumör i lilla bäckenet. Därutöver syftade avhandlingen 
till att fördjupa kunskapen om vilka andra faktorer som påverkar respektive markör 
och om nya möjligheter för tidig diagnostik existerar såsom cirkulerande tumör DNA 
(ctDNA) och somatiska mutationer detekterade med mutationsspecifik analys i 
vätskebaserade biopsier från genitaltrakten och i blodet. 
  
Vi genomförde en prospektiv multicenterstudie (studie I-III) och deltog som ett av 
flera centrum i en internationell multicenterstudie (studie IV) med syfte att förbättra 
diagnostik av EOC samt utvärdera potentiella metoder för framtida screening. Blod 
samlades in för analys av biomarkörerna CA125 och HE4. Risk of Malignancy Index 
(RMI), Risk of Ovarian Malignancy Algorithm (ROMA) och tre nya algoritmer 
utvärderades (GOT-1, GOT-2, GOT-3). I samband med inkluderingen noterades för 
varje patient andra variabler såsom förekomst av rökning, andra sjukdomar, längd, 
vikt och ärftlighet. Dessa utvärderades med multivariat regressionsanalys. 
Ultraljudundersökning genomfördes för bedömning av ovarialcystan/-tumören och 
beräkningar av algoritmerna Risk of Malignancy Index (RMI) och Risk of Ovarian 
Malignancy Algorithm gjordes (Studie I-III). Dessutom togs vätskebaserade biopsier 
från blodet, livmoderhals- och livmoderslemhinnan för analys av mutationer 
kopplade till gynekologisk cancer och cirkulerande tumör-DNA (ctDNA) i blodet. 
Formalinfixerade vävnadsbiopsier från tumörerna inhämtades från patologen och 
analyserades. PapSEEK, en metod för att upptäcka små mutationer i DNA eller 
kromosomavvikelser med gensekvensering, genomfördes på proverna från 
livmoder- och livmoderhalsslemhinnan, tumörvävnad och ctDNA i blodprov (studie 
IV).  
 
Studie I: Vid rekommenderad cut-off >35 visade biomarkören CA125 högst 
sensitivitet (SN) hos både pre- och postmenopausala patienter (Pre-M 95.7%; Post-
M 92.0%). Dessvärre erhölls en lägre specificitet (SP) vilket betydde en hög andel 
falskt positiva resultat (Pre-M 59.6%; Post-M 79.5%). Biomarkören HE4 hade en 
sämre sensitivitet än CA125, men specificiteten (SP) var högre både för pre- och 
postmenopausala kvinnor (Pre-M 90.9%; Post-M 92.1%). Algoritmerna RMI och 
ROMA var identiska i sin diagnostiska förmåga.  
 
Studie II: Tre nya algoritmer (GOT-1, GOT-2, GOT-3) utvärderades och de hade alla 
en bättre diagnostisk förmåga än RMI, ROMA eller CA125. Genom att addera HE4 
till CA125 eller RMI förbättrades specificiteten utan att sensitiviteten försämrades.  
 
Studie III: Förekomst av rökning, hjärt- och njursjukdom och endometrios bör 
övervägas när serumnivåer av CA125 och HE4 evalueras eftersom det finns fler 
falskt positiva svar bland de patienterna.  
 
Studie IV: PapSEEK-tekniken visade en mycket hög SP (98.6% livmoderhalsen; 
100% livmoderslemhinnan). När vi kombinerade vätskebaserad biopsi från 
livmoderhalsen och ctDNA i blodet förbättrades sensitiviteten för EOC till 63%, med 
en bibehållen hög specificitet på 100%. 
 
Sammanfattningsvis; vi fann i vårt material, en icke selekterad kohort av kvinnor i 
den västra delen av Sverige, att CA125 är en bättre markör för att identifiera kvinnor 
med cancer än HE4. HE4 är bättre än CA125 på att identifiera benigna 
ovarialcystor/tumörer i lilla bäckenet. Genom att kombinera nya och etablerade 
biomarkörer och algoritmer förbättrades den diagnostiska noggrannheten och 
andelen falskt positiva resultat minskade. Vi föreslår att HE4 bör implementeras i 
utredningen av ovarialcystor/-tumörer i lilla bäckenet av oklart ursprung för att 
minska antalet onödiga operationer. 
 
Det sista arbetet i avhandlingen visar att det är möjligt att upptäcka mutationer och 
ctDNA från ovarialcancer i vätskebaserade biopsier från blod, livmoderhals och 
livmoderslemhinna med hög specificitet. Avhandlingen demonstrerar potentialen i 
ett framtida protein- och genmutationsbaserat diagnostiskt test för en förbättrad tidig 
upptäckt av äggstockscancer (EOC) och testet kan eventuellt bli en metod för 
screening av äggstockscancer. 
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Abbreviations 
 
 
ARID1A  AT-rich interactive domain-containing protein 1A 
AUC  Area under the curve 
BMI  Body mass index 
BOT  Borderline type tumors 
BRAF  V-raf murine sarcoma viral oncogene homolog B1 
BRCA1/2  Breast cancer type 1/2 susceptibility protein 
CA125  Cancer antigen 125 
cfDNA  Cell-free DNA 
ctDNA  Circulating tumor DNA 
CI  Confidence interval 
CPH-1  Copenhagen index 1 
CT  Computed tomography 
CTC  Circulating tumor cells 
CTNNB1  Catenin-interacting protein-1 
EOC  Epithelial ovarian cancer 
DNA  Deoxyribonucleic acid 
eGFR  estimated Glomerular Filtration Rate 
ERBB2 (HER2) Avian erythroblastic leukemia viral homolog 2 
FDA  US Food and drug administration 
FIGO  International federation of Gynecology and Obstetrics 
GOT  Gothenburg index 
HE4  Human epididymis protein 4 
HGSC  High grade serous carcinoma 
IOTA  International Ovarian Tumor Analysis 
IL-8  Interleucin-8 
KRAS  Kirsten Rat Sarcoma Viral Oncogene Homolog 
LGSC  Low grade serous carcinoma 
MAF  Mutant Allele Fraction 
MCP-1  Macrophage chemoattractant protein-1 
MIA2G  Second generation multivariate index 
MRI  Magnetic resonance imaging 
NGS  Next Generation Sequencing 
NPV  Negative predictive value 
NÄL  Norra Älvsborgs Länssjukhus 
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OC  Ovarian cancer 
OVA-1  Multivariate index assay 
p53  Tumor protein p53 
PAD  Pathologic anatomic diagnosis 
Pap brush  Papanicolaou brush  
pet-CT  Positron emissions tomography CT 
PID  Pelvic inflammatory disease 
PIKC3CA  Phosphatidylinositol 3-kinase 
PLCO  The prostate, lung, colorectal and ovarian trial 
PPV  Positive predictive value 
Pre-M  Premenopausal 
Post-M  Postmenopausal 
PTEN  Phosphatase and Tenson Homologue 
RCC  Regional cancer center 
RMI  Risk of Malignancy Index 
ROC  Receiver Operating Characteristics 
ROCA  Risk of ovarian cancer algorithm 
ROMA  Risk of Malignancy Algorithm 
ROMA-P  Modified ROMA algorithm 
R-OPS  Rajavithi-Ovarian Cancer predictive Score  
SKAS  Skaraborgs Sjukhus Skövde 
SN  Sensitivity 
SP  Specificity 
STIC  Serous tubal intraepithelial carcinoma 
SÄS  Södra Älvsborgs Sjukhus   
TAO-brush Intrauterine sampling brush 
TP53  Tumor protein p53 gene 
TCGA  The Cancer Genome Atlas 
TVU  Transvaginal ultrasound 
UID  Unique identifier 
UKTOCS  The UK collaborative Trial of ovarian cancer screening 
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Introduction 
 
 
Epidemiology   
 
Incidence and prevalence   
Globally, more than 295,000 women are diagnosed with ovarian cancer (OC) every 
year, which accounts for 3.4% of all cancers among women (1, 2). The incidence 
varies geographically and the highest incidence is seen in the eastern (11.4 per 
100,000) and central parts (6.0 per 100,000) of Europe and in North America. The 
incidence is lowest in Southeast Asia and Africa (Figure 1) (2). In Sweden, the annual 
incidence is around 700 cases (2014), and OC, including tubal cancer, now 
constitutes roughly 3% of all female cancers (13/100,000 women), and has declined 
significantly compared to the 1970s (26/100,000) (3, 4). Ovarian cancer is found 
among women of all age groups, but it is rare under the age of 30. It is considered to 
be a disease mainly affecting postmenopausal women and the median age at 
diagnosis is 50-79 years (5). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Estimated age-standardized incidence rates of ovarian cancer (world). GLOBOCAN 
2018. 
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Mortality   
Ovarian cancer is the most lethal gynecological malignancy worldwide (6) and ranks 
as number seven most lethal cancer among women (2, 6). This is partly a 
consequence of the late stage of diagnosis, which today is our major clinical 
challenge (6). Because the disease typically does not present with symptoms in the 
early stages most, OC patients have a metastasized cancer already at diagnosis. This 
phenomenon has led to that we today have almost 185,000 deaths per year in OC 
worldwide (2). In Sweden disappointing statistical records have been reported with 
an average of 575 deaths every year (2012-2016 statistics) and the age-standardized 
mortality rate of 4.9 per 100,000 (Figure 2) (4). The 1-year and 5-year relative 
survival (RS) rates were of 87 and 49% (2016) (4). In fact, a woman´s lifetime risk 
for acquiring OC is 1 out of 75 and the estimated risk for death in OC is 1 out of 100 
(7). 
 
 
 
Figure 2. Estimated age-standardized rates of ovarian cancer age 0-85+ in Sweden. 
NORDCAN 2019. 
  
NORDCAN © Association of the Nordic Cancer Registries (18.2.2020) 
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Etiology   
 
The etiology of OC is complex and still not fully understood. Nearly 95% of OC is 
derived from the epithelial cells and frequently referred to as epithelial ovarian 
cancer (EOC). In this context it is worth noting that the coelomic epithelium is the 
epithelium that lines the surfaces of the abdominal cavity and abdominal organs. 
Hence, the coelomic epithelium covers the outermost layer of the female gonads and 
it develops into the peritoneum, pleura and the surface of the ovary. This epithelium 
is considered to be critically involved in the development of ovarian cancer. 
Noteworthy, metaplasia of the coelomic epithelium is also linked to endometriosis 
(8). During embryogenesis the coelomic epithelium will differentiate into granulosa 
cells upon XX-chromosome directed gonadal sex development. These cells 
eventually produce anti-Müllerian hormone (AMH) and allows the Müllerian ducts 
to develop. Therefore, the EOC is a heterogenous disease that differs in histologic 
subtypes, molecular features, gene expression, pathogenesis and prognosis (9, 10). 
Whereas, it has traditionally been viewed to evolve from epithelial cells overlaying 
the ovary, novel studies indicate that most cases of EOC originate from the fallopian 
tube epithelium, peritoneum or from the endometrium, associated with retrograde 
menstruation (11, 12). It is important to emphasize that a majority of OC, thus, 
originate from other gynecological tissues rather than from the ovary itself (1). My 
thesis will mainly focus on EOC and discuss this disease from many different aspects 
with special emphasis placed on improved differential diagnosis and early diagnosis 
in women with an ovarian cyst/pelvic tumor of unknown etiology. 
 
 
Tumor characteristics   
 
Histopathology   
The complex background of EOC has led to that we today divide EOC into subtypes, 
each with distinct morphological feature and biological behavior. The different 
histological subtypes differ with regard to their origin, cellular subtypes, molecular 
features, gene expression and pathogenesis (9). Five main types exist: 1) high-grade 
serous carcinoma (HGSC) (70%), 2) endometrioid carcinoma (10%), 3) clear cell 
carcinoma (10%), 4) mucinous carcinoma (3%) and 5) low-grade serous carcinoma 
(LGSC) (<5%) (Figure 3) (9, 13). Moreover, there are smaller histological types such 
as seromucinous tumors, Brenner tumors, carcinosarcomas and undifferentiated 
tumors. Both HGSC and some LGSC are believed to arise from the fallopian tube 
epithelium and the fimbriated end (11, 14, 15). However, the five main types are 
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essentially different tumors and, therefore, constitute different diseases. LGSC are 
associated with borderline tumors and unrelated to hereditary mutations, such as 
breast cancer type 1/2 susceptibility protein (BRCA1/2) and the Tumor protein p53 
(TP53) mutations. HGSC, on the other hand, is not associated with borderline tumors 
and typically harbor TP53 mutations and BRCA abnormalities. Endometrioid 
carcinoma, clear-cell carcinoma and seromucinous carcinomas, are possibly 
associated with endometriosis (16-18). Finally, the origin of mucinous tumors are 
unknown but some authors suggest they most likely originate from transitional cells 
at the tubal-mesothelial junction or are metastasis from the gastrointestinal tract 
(Figure 3) (19, 20). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Suggested origin of the EOC “main” subtypes. (Illustration  Jan Funke) 
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Borderline tumors are a subgroup of epithelial tumors of low malignant potential, as 
they do not invade the stroma. This is in contrast to the epithelial carcinomas, which 
readily invade the surrounding stroma. In comparison to benign epithelial tumors 
(adenomas), borderline tumors can be considered as atypical proliferating epithelium 
with nuclear atypia. The most common borderline tumors are the serous (55%) and 
mucinous (40%) types (12). The incidence is 150 cases annually in Sweden, and 
these tumors account for almost 30% of all epithelial tumors among women under 
the age of 40 (21). Of note, it is difficult to separate them from malignant tumors 
when using imaging techniques, such as transvaginal ultrasound (TVU) and 
computed tomography (CT), and hence complementary diagnostic tools need to be 
employed. As surgical removal of malignant tumors is an immense challenge there 
is a need for improved diagnostic tools, especially, since many of the patients with 
borderline type tumors (BOT) or benign cysts are still fertile and would benefit 
greatly from less extensive surgery or no surgery at all. 
 
Stage and grade   
The recommendations made by the International Federation of Gynecology and 
Obstetrics (FIGO) are used for staging of EOC. FIGO Stage I-IV, with a higher stage 
for a more advanced disease, are dependent on their growth path and metastatic 
status, which has prognostic significance and is also critical for the choice of 
treatment (Figure 4) (22, 23). Typically a majority (75%) of women diagnosed with 
EOC have a late stage disease, FIGO III+IV, 5-year survival of <30%. Consequently 
there is a clear need for earlier diagnosis as the early stage FIGO I+II carries a much 
better prognosis with a 5-year survival of almost 90%. Thus, early detection is one 
of the keys to improve the prognosis for EOC patients (24). 
 
The grading of EOC is done according to World Health Organization (WHO) 
published in 2015 (25). However, during the course of this thesis work, a shift in 
grading has been implemented due to the improved knowledge about molecular and 
genetic features of OC. Therefore, we have used both the old and new systems as 
both tumor stage according to FIGO and type and grade according to WHO critically 
influence the choice of treatment of EOC. The serous tumors were previously graded 
according to Silverberg et al and therefore, so were our tumors (26). They were 
divided into 3 groups (grade 1-3) according to the type of growth, cytological atypia 
and presence of mitosis. Initially we also used the grading system for endometrioid 
ovarian cancers as defined for endometrioid tumors in the uterus:  
1. Grade 1: well differentiated, with <5% non-squamous or non-morular solid 
tumor growth. 
 Introduction 
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2. Grade 2: moderately differentiated, with 5-50% non-squamous or non-
morular solid tumor growth. 
3. Grade 3: poorly differentiated, with >50% non-squamous or non-morular 
solid tumor growth. 
 
The tumor grade was raised by 1 step if nuclear atypia was present.  
 
The new classification system for EOC involves, as previously, no grading for 
mucinous and clear-cell type. Seromucinous is a new entity which is associated with 
endometriosis, and because they harbor AT-rich interactive domain-containing 
protein 1A (ARID1A) mutations they are more closely related to endometrioid 
tumors than serous carcinoma (25, 27). Serous- and endometrioid carcinoma are 
divided into low-and high grade tumors and graded accordingly (25). In fact, 
previous high-grade endometrioid tumors have been redefined as HGSC (9, 27).   
 
STAGE I:  Tumor confined to ovaries 
 IA Tumor limited to 1 ovary or fallopian tube, capsule intact, no tumor on surface,  
  negative peritoneal washings and ascites. 
 IB Tumor involves both ovaries or fallopian tubes, otherwise like IA. 
 
 IC Tumor limited to 1 or both ovaries or fallopian tubes including 
 IC1 Surgical spill. 
 IC2 Capsule rupture before surgery or tumor on ovarian or tubal surface. 
 IC3 Malignant cells in the ascites or peritoneal washings. 
  
STAGE II:  Tumor involves 1 or both ovaries or the fallopian tubes with pelvic extension (below the  
 pelvic brim) or primary peritoneal cancer 
 IIA Extension and/or implant on uterus and/or Fallopian tubes. 
 IIB Extension to other pelvic intraperitoneal tissues. 
  
STAGE III:  Tumor involves 1 or both ovaries, or fallopian tube, or a primary peritoneal cancer with  
 cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or  
 metastasis to the retroperitoneal lymph nodes 
 IIIA  (Positive retroperitoneal lymph nodes and /or microscopic metastasis beyond the  
  pelvis.) 
 IIIA1 Positive retroperitoneal lymph nodes only. 
 IIIA1(i)  Metastasis ≤10 mm. 
 IIIA1(ii)  Metastasis >10 mm. 
 IIIA2 Microscopic, extra pelvic (above the brim) peritoneal involvement ± positive 
retroperitoneal lymph nodes. 
 IIIB Macroscopic, extra pelvic, peritoneal metastasis ≤2 cm ± positive  
  retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen. 
 IIIC Macroscopic, extra pelvic, peritoneal metastasis >2 cm ± positive  
  retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen. 
  
STAGE IV:  Distant metastasis excluding peritoneal metastasis 
 IVA Pleural effusion with positive cytology. 
 IVB Hepatic and/or splenic parenchymal metastasis, metastasis to extra abdominal  
  organs (including inguinal lymph nodes and lymph nodes outside of the abdominal  
  cavity). 
 https://www.sgo.org/wp-content/uploads/2012/09/FIGO-Ovarian-Cancer-Staging_1.10.14.pdf  
 
 
Figure 4. Staging of ovarian-, tubal- and primary peritoneal cancer according to FIGO. 
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Dualistic model -Type I and Type II   
It is important to note that major advances in our understanding of the pathogenesis 
of EOC have occurred during the past decades.  In particular, the strong link between 
EOC and the fallopian tube epithelium rather than to the ovary itself has been in 
focus. HGSC arises from precursor lesions, serous tubal intraepithelial carcinoma 
(STIC), in the fallopian tube. Localized to the distal fallopian tube or the fimbria in 
particular, and not from the ovary (28).  This was first described in patients with a 
hereditary risk of OC, i.e. carriers of BRCA1/2 mutations, who were offered to 
undergo risk-reducing salpingo-oophorectomy (RRSO) (29-31). In the surgical 
specimens, STIC was found as well as TP53 mutations, in particular. Since the same 
TP53 mutations were only found in the fallopian tube of these women, it was argued 
that HGSC, must be derived from the fallopian tube and not from the ovary itself 
(27, 32, 33). Based on these data Kurman et al proposed a novel progression model 
including both morphological and molecular features. This simplifying model 
divides EOC into two different types of tumors; type I and type II (Figure 5) (12, 27, 
33-36). 
 
Type I cancers are typically large, cystic and sometimes unilateral. They develop 
from benign changes implanted in the ovary, which over time become malignant. 
They are slowly growing and genetically stable (9, 27). Type I tumors comprise of 
low-grade serous, endometrioid, clear-cell, seromucinous (also called mixed 
Müllerian tumors), mucinous and Brenner (transitional) tumors. They are proposed 
to derive from endometriosis sc. endometriosis related tumors (which include 
endometrioid, clear-cell and seromucinous carcinomas), fallopian tube or primarily 
the ovary (LGSC), germ cells (mucinous carcinoma) and transitional cells (mucinous 
carcinoma and Brenner tumors) (27, 37). Except for clear cell carcinomas, type I 
tumors are considered to be low-grade tumors. Type 1 tumors carry mutations in 
mismatch repair proteins and signaling proteins involved in cell proliferation  such 
as, V-raf murine sarcoma viral oncogene homolog B1 (BRAF), Kirsten Rat Sarcoma 
Viral Oncogene Homolog (KRAS), beta-catenin, Phosphatase and Tenson 
Homologue (PTEN), ARID1, Avian erythroblastic leukemia viral homolog 2 (ERBB 
(HER2)) but TP53 mutations are not seen (Figure 5) (9, 27, 38). Type I tumors are 
generally restricted to the ovary when diagnosed (stage 1), and, therefore, they have 
a more favorable prognosis (9). 
 
Type II tumors account for 75% of all EOC, but are responsible for 90% of all deaths 
from OC, because they are usually diagnosed at an advanced stage (Table 1) (33, 39). 
Despite the fact that the response rate to adjuvant chemotherapy is 75%, relapses 
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occur frequently, and the five-year survival rate is <30% (40). The EOC originates 
from the fallopian tube epithelium and precursor lesions, STIC, and can develop into 
aggressive invasive tumors located in the fallopian tube, peritoneum or the ovary. 
They are characterized by TP53 mutations and are more aggressive, fast growing, 
and chromosomally instable and harbor frequent amplifications and deletions 
compared to the slow-growing type I tumors (Figure 5) (9, 27, 38). Type II tumors 
include HGSC, carcinosarcoma and undifferentiated carcinomas. TP53 mutations are 
seen in nearly all HGSC patients and in 20% of these tumors also BRCA1/2 
mutations are identified (Table 1) (10, 41). Tumors that previously were classified 
as high grade endometrioid are now classified as HGSC since they also harbor TP53 
mutations (27, 42). 
 
Tumors with endometrioid and serous histology are in early stage disease assumed 
to be associated with a better outcome compared to mucinous and clear-cell histology 
(40, 43). Clear-cell carcinomas are often diagnosed in an early stage, but are more 
often associated with a higher frequency of lymph node metastasis (44).   
 
 
Table 1. Features of the five major subtypes of ovarian carcinoma. 
 High-grade 
serous carcinoma 
Low-grade 
serous carcinoma 
Endomterioid Clear-cell Mucinous 
Frequency 70% <5% 10% 5-10% 3% 
Low- or high-
grade 
High-grade Low-grade Low-grade High-grade Low-grade 
Dualistic model Type II Type I Type I Type I Type I 
Precursor lesions Serous tubal 
intraepithelial 
carcinoma (STIC) 
Low-grade 
malignant lesions, 
serous BOT 
Endometriosis, 
retrograde 
menstruation 
Endometriosis, 
retrograde 
menstruation 
Low-grade 
malignant lesions, 
mucinous BOT 
Genetic risc BRCA1/2  HNPCC/Lynch   
Molecular 
abnormalities and 
common mutations 
TP 53, BRCA1/2 KRAS, BRAF PTEN, ARID1A, 
CTNNB1, 
PIK3CA, KRAS, 
CDKN2A, BRAF 
ARID1A, 
PIK3CA, 
CTNNB1, PTEN, 
KRAS 
KRAS, CDKN2A, 
PTEN 
Usual stage at 
diagnosis 
Advanced Early or advanced Early Early Early 
Prognosis Poor Favorable Favorable Intermediate Favorable 
 
Summary overview to highlight differences in origin, prognosis and genetics. 
BOT=borderline type tumors, BRCA1/2=breast cancer type 1/2 susceptibility protein, 
HNPCC=hereditary nonpolyposis colorectal cancer  
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Figure 5. EOC subtypes according to type I and II tumors and the low- and high-grade 
pathway.  
 
STIC=serous tubal intraepithelial carcinoma, LOH=Loss of heterozygocity, LGSC=low-grade serous 
carcinoma, HGSC=High-grade serous carcinoma. (Illustration  Jan Funke) 
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Risk factors for EOC   
 
A number of factors have been associated with an increased risk of EOC including 
age, obesity, nulliparity, familial history of ovarian cancer and inherited genetic 
mutations (45). However, genetic inherited mutations are associated with only 5 to 
15% of all OC. The most common mutations are BRCA1 and BRCA2, which will 
be discussed later. Women who have a genetically increased risk of developing OC 
may benefit from risk-reducing prophylactic surgery after childbirth (46). 
Noteworthy is that the risk of OC is 3% if you have a first-degree relative with OC  
and about 15-20% if the patient has a known  hereditary risk (47). Also, there might 
be an increased risk of EOC in women who use hormone replacement therapy (HRT) 
and in particular estrogen only treated women (48, 49). 
 
The relationship between endometriosis and EOC was first described in 1925 by 
Sampson et al. (50). Between 5- and 15% of the female population suffers from 
endometriosis and there is an increased risk for clear cell cancer (RR OR 3.05 95% 
CI 2.43-3.84) and endometrioid cancer (RR OR 2.04 95% CI 1.68-2.48) (51).  In a 
Danish case-control study the relationship between endometriosis and ovarian cancer 
was shown by the standardized incidence ratio (SIR) to be 1.34 (CI 1.16-1.55) 
endometrioid (SIR=1.64 (CI 1.09-2.37)) and clear-cell carcinoma (SIR 3.64 (CI 
2.36-5.38)) (52). Moreover, endometriosis is detected in 30-55% of all clear cell 
cancers and in 30-40% of all endometrioid cancers. Endometriosis associated ovarian 
cancer is more often detected in younger women and more often in earlier stages 
(53). This being said the overall risk of EOC in women with endometriosis is low, 
only 3%, and therefore prophylactic bilateral salpingo-oophorectomy (BSO)  
is not currently recommended as for BRCA1/2 carriers. Genes associated with 
endometriosis are the tumor suppressor genes TP 53 (5%), ARID1A (50%) and 
PTEN (20%), as well as the oncogene KRAS (10%) (36, 53). 
 
Endometriosis has been proven correlated to increased risk of ovarian cancer, 
especially type I endometrioid carcinoma (54). There have been controversies 
whether other factors of infertility are directly associated with an increased risk of 
ovarian cancer, although a high number of ovulations and nulliparity have been 
shown to be associated with an increased risk for EOC (54, 55). The use of fertility 
medications and the possible increased risk for development of EOC has been 
controversial and different study results are contradictory but seem to diminish the 
effect of infertility treatment (56, 57). Nevertheless, during the past decade an 
explosion of different drugs and treatments have occurred and the impact of 
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infertility or rather treatment of infertility on risk for EOC must be considered in new 
trials. 
 
Smoking is yet another known risk factor for EOC with a 50% increased risk for 
mucinous ovarian carcinoma, while there is no increased risk to develop the other 
subtypes of OC. On the contrary smoking actually were defined with a tiny decrease 
in endometrioid and clear-cell carcinomas. This could have to do with the cellular 
origin of the cancer, endometrioid or clear cell carcinomas (58). 
 
 
Protective factors   
 
Several factors have been identified to be associated with a lower risk for the 
development of EOC. A clear risk reduction has been noted for tubal ligation, 
hysterectomy, parity (especially the first child) as well as a low number of ovulations 
(54, 55). It should be noted that oral contraceptives that inhibit ovulation have a 20% 
risk-reducing effect for every 5-year period of use (45, 58). The protective effect is 
considered to be associated with reduced number of ovulations and continuous even 
after cessation of treatment (45, 58). Also breastfeeding reduce the life-time risk of 
EOC (55, 59). Moreover, tubal ligation has been found to reduce the risk for the 
development of EOC. The largest reduction was seen for endometrioid carcinoma 
(52%), clear cell carcinoma (42%), but also aggressive mucinous carcinoma (32%) 
as well as HGSC (20%) (60, 61). In addition, prophylactic oophorectomy in BRCA-
positive women has been found to reduce the risk for EOC by 75% (62).   
 
The prophylactic procedure is often performed in premenopausal women with 
negative effects on the cardiovascular system and unwanted menopausal symptoms. 
Promising results have shown a risk reduction after salpingectomy with 35-50%. A 
pooled meta-analyses concluded that the evidence towards the benefit of 
opportunistic salpingectomy for lifetime risk reduction for EOC were insufficient 
due to the insufficient evidence and possibly endocrine drawbacks as reported by 
Muka et al. (63, 64). The results from the two ongoing Swedish national RCT trials 
hysterectomy and opportunistic salpingectomy (HOPPSA) and salpingectomy at 
time for sterilization (SALSTER) will therefore be exciting. 
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Diagnosis   
 
The early symptoms of OC are nonspecific and include bloating, dyspepsia, gas pains 
and backache (65). The routine examination of patients with pelvic symptoms 
include biomarkers, TVU and bimanual palpation with clinical evaluation (66, 67). 
Because clinical signs and symptoms are vague and the examination and laboratory 
testing are seldom conclusive there is an urgent need to improve our efforts to 
develop better tools and protocols to make early and accurate diagnosis possible. 
Needless to say, today we experience both a doctor’s and a patient’s delay in 
diagnosing EOC (65). Moreover, due to the low incidence of EOC, early detection 
strategies must achieve a high sensitivity >75%, and an even higher specificity 
>99.6% to achieve a positive predictive value (PPV) of at least 10% (68, 69). There 
is an urgent need for improved early detection of OC and much better differential 
diagnosis to improve the five year survival rate. Additionally, due to the high false 
positive diagnostic results not only unnecessary surgical complications with 
increased morbidity can be encountered, but additional hormonal substitution is 
required as there is an increased risk for cardiovascular mortality in these women 
(63). 
 
There is growing evidence that screening for OC can improve the clinical outcome 
for the patients. In several countries, including Sweden, there are screening programs 
for breast-, colon- and cervical cancer, associated with a significant reduction in 
mortality (70-72). The key to success is the understanding of the natural history of 
the cancer and the existence of precursor lesions that can be diagnosed and treated 
(71). A screening test should be validated, reproducible, non-invasive and 
inexpensive. More importantly, the test should have a high specificity and negative 
predictive value (NPV) to avoid the false positive cases. For diseases with a low 
prevalence in the population, such as EOC, we require from the screening test a very 
high specificity and sensitivity (>75%) (73, 74). However, the high frequency of 
false positive cases in OC screening is highly problematic and this is why general 
screening for EOC cannot be recommended yet (75). Diagnostic tests should be used 
in women who has symptoms with the intention to identify patients with risk of 
having a malignancy. A diagnostic test requires a high sensitivity and positive 
predictive value (PPV) to avoid false negative testing. High specificity is also 
preferable, due to low count of false positive test results. Unfortunately, the current 
diagnostic tools allow us to bring together clinical assessments, CT scan, TVU and 
laboratory testing for markers that are not restricted solely to EOC (76). This 
combination does not adequately discriminate between EOC and benign tumors. 
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Hence, there is a significant overrepresentation of benign cases that are subject to 
surgery and, therefore, too many women, including those with benign tumors, are 
castrated with subsequent requirement for hormonal substitution (77). 
 
Imaging techniques   
There are different methods to diagnose ovarian cyst and other pelvic tumors. The 
different methods aims to facilitate mapping of tumor spread and to be of help in the 
pre-operative decision of possible treatment strategies. These different methods 
include CT, magnetic resonance imaging (MRI), positron emissions tomography CT 
(Pet-CT), and clinical assessment in combination with ultrasound. 
 
CT has a limited value when it comes to evaluation of tumors in the small pelvis. 
The method is rarely specific and is more often used when it comes to evaluating 
metastasized disease. MRI is the one of the imaging techniques that has the greatest 
specificity and sensitivity in separating benign from malignant tumors (78). PET-CT 
is not frequently used whereas TVU is the first choice for evaluation of a suspect 
adnexal tumor. It is easy to use, available at most gynecological clinics and 
inexpensive compared to other imaging methods, and the adnexal findings can be 
classified according to different TVU algorithms. The international ovarian tumor 
analysis group (IOTA) have developed criteria and definitions for diagnosing ovarian 
tumors (79, 80). Simple rules are categorized with five malignant (M) and five benign 
(B) criteria’s, were the definition of benign includes no M criteria present (79, 80). 
With the “pattern recognition” adnexal tumors can be classified according to 
ultrasound criteria. An experienced TVU expert can separate malignant from benign 
tumors with a sensitivity and specificity of 90% and 94%, respectively (81). 
 
In this thesis work classifications according to the Risk of Malignancy Index (RMI) 
criteria, presented below were used (82, 83). 
 
Biomarkers   
A diagnostic biomarker is one that detects and confirms disease and it must be 
reliable, precise and its detection must be reproducible (84). Moreover, it can also be 
used to monitor the status of a disease condition following treatment and alert for 
signs of relapse (84). A tumor biomarker for clinical use takes time to establish and 
it happens stepwise from its initial discovery in the neoplastic tissue to the 
translational and clinical phases of application (85, 86). Finally, successful clinical 
implementation of a biomarker and its diagnostic importance, complementing other 
tools, is often cumbersome and slow. Nevertheless, novel biomarkers will become 
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available as we introduce liquid biopsies, which allows for analyze of cell-free 
deoxyribonucleic acid (cfDNA), circulating tumor DNA (ctDNA), exosomes and 
microRNA and the use of epigenetic biomarkers for diagnosing EOC in a more 
personalized way (87). Indeed, we already have several new biomarkers for EOC 
found either in blood, urine or ascites (88, 89). However, at present only few of these 
biomarkers have been approved by the U.S Food and drug administration (FDA) for 
clinical use. Still the most appreciated biomarkers for EOC are the Cancer Antigen 
125 (CA125) and Human epididymis protein 4 (HE4) antigens. I will briefly 
summarize what we know about these biomarkers.   
 
CA125   
The discovery of CA125, a transmembrane glycoprotein encoded by the MUC 16 
gene located to chromosome 19, became important in the diagnosis of OC (90-92). 
However, CA125 was only approved for monitoring treatment and for detecting 
recurrence of disease by the FDA, and not for preoperative diagnosis (76, 92, 93). 
Serum levels of CA125 are elevated (>35 U/mL) in 80% of EOC-patients in stages 
III and IV, but in early stages <50% of EOC score positive for CA125 (94). In 
addition, this biomarker is elevated in only 30-50% of mucinous cancers, therefore, 
only a significant correlation between histopathological scoring, FIGO stage and 
preoperative CA125 levels are seen in a minority of EOC cases (42, 94-96). 
Unfortunately, the serum CA125 levels can also be elevated in other, both benign 
and malignant diseases, affecting pleura, pericardium or the peritoneum. These non-
specific reactions make CA125 less useful as a diagnostic tool for EOC. In fact, 
cervical-, breast-, colon-, pancreatic-, lung-, gastric- and liver cancer can all exhibit 
elevated CA125 serum levels (97-99). Also, benign gynecological disorders 
including endometriosis, pregnancy, menstrual cycle variations, pelvic inflammatory 
disease (PID), myoma, salpingitis as well as other non-gynecological conditions, 
such as cirrhosis, peritoneal inflammation, pericarditis, renal failure, liver disease 
and congestive heart failure, can exhibit elevated serum CA125 levels (100-104). 
Serum levels of CA125 are, therefore, a poor diagnostic tool for EOC in early stage 
and it is critical to know that false positive CA125 serum levels may be found in 
fertile woman. Thus, CA125 is not a specific biomarker for OC.   
 
HE4   
Attempts in the early 90’s to identify complementing biomarkers for improved and 
early detection of EOC resulted in the discovery of the human epididymis 4 (HE4) 
antigen (105). Similar to CA125 it is a glycoprotein that is overexpressed in some 
EOC patients. It was first thought to be a more promising biomarker for EOC than 
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CA125 (106, 107). However, it turned out that HE4 could not be detected in some 
types of EOC and, therefore, HE4 cannot be used as a stand-alone diagnostic marker 
for EOC. HE4 is a low molecular weight (13 kilodalton) protein, member of the whey 
acidic proteins (WAP)-gene family of protease inhibitors. These proteins are 
characterized by nearly 50 amino acid long sequences with eight highly conserved 
cysteine residues forming four disulfide bridges (108). The mature glycosylated 
secretory form (25 kilodalton) contains two WAP four-disulfide core (WFDC) 
domains encompassing the eight cysteine residues, and is encoded from chromosome 
20q12-13.1(109). Elevated serum levels of HE4 are found to be highly associated 
with endometrioid (100%) and serous carcinomas (93%), whereas only 50% of clear 
cell carcinoma and 0% of cancers with  mucinous histology show enhanced levels of  
HE4, similar to CA125 (86, 110). Unlike assessments of CA125 levels, no standard 
cut-off level has been agreed on for HE4 and, hence, different cut-off levels are used 
by different manufacturers. This is problematic, but an even more confounding factor 
is the fact that HE4 levels are increased by age (111-115). Nevertheless, serum HE4 
levels have been shown to have a higher sensitivity than serum levels of CA125 for 
diagnosing EOC of stage I and stage III-IV in fertile women (116-122).  Importantly, 
in contrast to CA125, HE4 is not elevated during pregnancy or in endometriosis (112, 
113, 116, 123, 124). However, women suffering from renal failure or smokers can 
have elevated levels of serum HE4 (125). 
 
Several studies have compared the diagnostic value of HE4 as opposed to serum 
CA125 determinations but the results are difficult to compare due to different 
analytical platforms, used cut offs and compositions of study populations (116-122). 
Several groups have calculated optimal cut offs for their study population or used 
statistical fixed thresholds such as a specificity of 75%. Using different analytical 
platforms have shown to give rise to a difference in marker value of up to 14% (111).  
In addition to analyzing CA125 and HE4 alone, several groups have also evaluated 
a combination of these indicating a higher diagnostic accuracy than used alone (121, 
122, 126, 127). 
 
Algorithms   
RMI    
Because serum levels of CA125 or HE4 alone are not conclusive for diagnosing EOC 
several combinations with other parameters have been developed and implemented. 
In particular, the combination of these biomarkers, menopausal status and TVU in 
an algorithm, Risk of Malignancy Index (RMI), was developed in the 1990s to 
facilitate the referral of patients to the gynecologists (82). RMI predicts whether the 
 Introduction 
28 
 
pelvic mass is a cancer or a benign cyst and it is based on a combination of serum 
CA125 levels, ultrasound findings and menopausal status. RMI relies on gynecologic 
ultrasound expertise. The RMI assessment has been modified by Tingulstad et al. 
into RMI 2 in 1996 and further modified into RMI 3 in 1999 (83, 128). The 
differences between RMI 1, RMI 2 and RMI 3 include an increased emphasis on 
ultrasound findings and menopausal status (Figure 6). All of the algorithms (RMI I-
III) recommends a cut-off value of 200. 
 
 
RMI calculation U x M x CA125 
  
RMI 1 Ultrasound (U) 0=imaging score 0 
Jacobs et al. 1996 (73)  1=imaging score 1 
  2=imaging score 2-5 
  
 Menopause (M) 1=premenopausal 
  3=postmenopausal 
RMI 2 Ultrasound (U) 0-1=imaging score 1 
Tingulstad et al. 1996 (112)  2-5=imaging score 4 
  
 Menopause (M) 1=premenopausal 
  4=postmenopausal 
RMI 3 Ultrasound (U) 0-1=imaging score 1 
Tingulstad et al. 1999 (74)  2-5=imaging score 3 
  
 Menopause (M) 1=premenopausal 
  3=postmenopausal 
 
Cut-off for RMI >200 increased risk for EOC 
 
Figure 6. Algorithm for the Risk of Malignancy Index (RMI) calculations. 
Overview of the different RMI calculations (RMI I-III). Differences in values of ultrasound 
calculation and menopausal status as visualized.  
 
EOC=Epithelial ovarian cancer. 
 
 
ROMA   
Another algorithm developed for EOC differential diagnostics is named Risk Of 
Malignancy Algorithm (ROMA), and was developed as a tool to triage patients into 
high or low cancer risk and to find appropriate clinical treatment (118). In contrast 
to RMI, the ROMA algorithm uses serum levels of both HE4 and CA125 as well as 
the menopausal status, but ultrasound investigations are not included (Figure 7). 
Because ultrasound is not used it is believed that ROMA is particularly suitable for 
primary care (118). 
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Figure 7. Algorithm for calculation of the Risk of Malignancy Algorithm (ROMA). 
 
Moore et al. Gynecol Oncol. 2009;112(1):40-6 (ref 117). 
 
 
The human genome, DNA Helix and mutations   
The human body has approximately 200 different cell types. As cells die and get 
replaced by new cells it is through cell division, a process that is strictly regulated by 
specific genes. The human genome consists of over 22.000 genes and a majority of 
these genes encode different proteins that regulate or are responsible for various 
cellular functions. This is why all changes in cell function can be monitored through  
different protein activities. It is, thus, important to remember that tumor development 
is a consequence of gene mutations, deletions, rearrangements and altered gene 
regulation and is also reflected in the change of protein functions (10, 129). The 
mechanism behind cancer development is complex and not fully understood, but 
genetic changes are frequently found in cancer cells. In fact, genomic instability 
(GIN) is a hallmark of cancer development with single nucleotide changes to large-
scale cytogenetic alterations (129). Subsequently, GIN can affect not only DNA 
replication and cell cycle progression and checkpoint control, but also have an effect 
on chromosome segregation and DNA repair. Two main groups of GIN exist: 1) 
nucleotide instability and 2) chromosomal instability (CIN), including chromosomal 
rearrangements. Hence, GIN is strongly correlated to tumor progression and 
associated with poor prognosis. Cancer genomes are often highly complex and 
contains several mutations besides alterations in chromosomes. Tumor protein p53 
(p53) is one of the proteins counteracting GIN (130). In general p53 activates cell 
cycle arrest and loss of p53 allows cancer cells to develop (131). The EOC with most 
prominent TP53 mutations is the HGSC. 
 
Another abnormality is aneuploidy, which is when the cell has an abnormal number 
of chromosomes. Detection of aneuploidy has sparked new hope in early diagnosis 
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of EOC as >90% of the cancers host aneuploidy and in particular ovarian and 
endometrial cancers have abnormalities located on chromosomes 7q and 8q (132). 
 
Next generation sequencing and early EOC diagnosis   
Today a biomarker does not necessarily has to be a protein detected in blood or any 
other body fluid. The detection of single cells with genetic changes associated with 
cancer development is a growing field and much hope exist as to that this technology 
will help early diagnosis of EOC. To facilitate such investigations liquid biopsies 
have been introduced and whole cells or cell free DNA (cfDNA) can be sampled and 
analyzed. In this way we get access to circulating tumor DNA (ctDNA) or mRNA. 
ctDNA is likely derived from apoptotic cells and can therefore represent a specific 
tumor marker (133). The next generation sequencing (NGS) technology platform has 
revolutionized detection of genetic cancer abnormalities and uses a massively 
parallel sequencing (MPS) strategy, to provide high-throughput sequencing that 
rapidly can screen millions of DNA or RNA strands.  NGS can be used to analyze 
the presence of specific mutations or whole genome abnormalities. Thus, the NGS 
technology allows us to sequence the whole genome or shorter genomic regions at a 
very high speed with excellent resolution. This possibility has accelerated the work 
to identify new mutated genes or other genetic abnormalities in cancer cells. Further 
expectations are that the NGS technology will help us to diagnose EOC at an early 
stage as well as suggest appropriate treatment for a particular cancer.      
 
Because EOC grow with cystic compartments, originate in the fallopian tube and can 
metastasize through the blood or in the peritoneum we can expect to find circulating 
tumor cells (CTC), ctDNA or tumor DNA in not only blood but also in urine, cyst 
fluids, cervical and endometrial smears. These cells or their DNA can be sampled 
and subjected to NGS analysis (134, 135). If we can identify tumor specific mutations 
in these liquid biopsies it may also be possible to diagnose cancers at an early stage 
and be used for screening purposes. The fast development of NGS and advanced 
DNA or RNA sequencing has enabled a promising new arsenal of non-invasive 
diagnostic possibilities. It is expected that future improvements of these techniques 
will greatly help in early diagnosis of EOC and, subsequently, the much improved 
success of treatments of these cancers, personalized treatment, treatment response 
monitoring and early relapse detection (135). 
 
Somatic and germline mutations-option for diagnosis?   
The somatic mutations that are most important for the onset of EOC are tumor 
suppressor genes such as TP53, BRCA1/BRCA2 and PTEN (18).  
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Mutations in PTEN have been found in both endometriosis-associated ovarian cancer 
and in benign endometriosis cysts. ARID1A is present in 50% of clear cell and in 
40% of endometrioid cancers (136). Also, signaling pathway genes, such as KRAS 
and ERBB2 have been found to carry mutations as TP53, which is involved in DNA 
repair processes (Table 1). BRCA1/2 mutations are detected in almost 20% of HGSC 
(41). For women under the age of 40 who carries BRCA1/2, the risk for EOC is 3%, 
and can increase to 10% by the age of 50 (137) . The successively increasing risk for 
EOC up to the age of 80 is higher for carriers of BRCA 1 (49%) than for carriers of 
BRCA 2 (21%) (138). For carriers of BRCA1/2 gene mutations diagnosed with EOC, 
the HGSC is the most common type. Another hereditary condition with EOC is 
associated with Lynch syndrome, also called hereditary nonpolyposis colorectal 
cancer (HNPCC), and Lynch syndrome is also associated with endometrial 
carcinoma (27-71%). Approximately 90% of patients with Lynch syndrome have a 
mutation in either mutL homolog 1 (MLH1) or mutS homolog 2 (MSH2) and 
synchronous endometrial cancer is detected in 20% of the women diagnosed with 
EOC (139). Additionally, mutations in BRCA1 interacting protein C-terminal 
helicase 1 (BRIP1), RAD51 paralog C (RAD51C) and RAD51 paralog D (RAD 
51D) are associated with an increased risc for EOC among women over 50 years of 
age. At present no other malignancies are highly associated with pathogen variants 
of these genes (140, 141). Genes associated with endometriosis are the tumor 
suppressor genes TP 53 (5%), ARID1A (50%) and PTEN (20%), as well as 
oncogenic KRAS (10%) (36, 53).   
 
 
Prognostic factors   
 
Several prognostic factors have been identified for EOC. For example, the 
Gynecologic Oncology Group (GOG) studies in the early 90’s identified presence of 
age, ascites, residual disease and histological type to be critical for the prognosis 
(142, 143). Especially age has been consistently identified as an independent 
prognostic factor for the outcome of OC (43). Indeed, the prognostic effect of a 
younger age was persistent even after adjustments for stage, grade and surgical 
treatment of OC (5). Moreover, almost 30% of patients with EOC are diagnosed with 
a stage 1 cancer with a 5-year overall survival of >80% (144). 
 
Residual tumor after cytoreductive surgery is another important independent factor 
for the outcome of EOC (43, 145-147). Bristow et al performed a meta-analysis and 
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included nearly 6900 women with advanced EOC, and found that with every 10% 
reduction of residual tumor tissue the median survival of the patient group increased 
by 5.5%. Improved survival was observed with a residual tumor of <10 mm after 
surgery (43, 147). Of course, no remaining residual disease after cytoreductive 
surgery will give the highest progression free survival (PFS) and overall survival 
(OS) (147, 148). Therefore, referral of patients with advanced OC to specialized 
tertiary surgical centers for cytoreductive surgery is warranted and should be given 
the highest priority (147, 149, 150).      
33 
 
Aims 
 
 
The overall aim of this project was to evaluate new and established biomarkers and 
algorithms in order to optimize accurate diagnosis of EOC and to eliminate any 
differential diagnosis in women with unclear tumors in the small pelvis. The ultimate 
aim was to improve early diagnosis of EOC so that more tumor specific treatments 
can be developed. 
 
The specific objectives of this PhD project were: 
 To test the hypothesis that the biomarker HE4 and algorithm ROMA will 
improve early detection and differential diagnosis in an unselected population 
of women diagnosed with an unknown ovarian cyst/pelvic tumor compared to 
CA125 and RMI (Paper 1). 
 To test the hypothesis that adding biomarkers or ultrasound measurements to 
already established algorithms or biomarkers will improve differential 
diagnosis of EOC (Paper 2). 
 To test the hypothesis that HE4 assessments improve differential diagnosis in 
women with a benign ovarian disease and moreover increase our knowledge 
about different potential confounders affecting CA125 and HE4 (Paper 3). 
 To test the hypothesis that new approaches, using somatic mutation analysis 
from liquid biopsies in combination with analysis of circulating tumor DNA 
and aneuploidy, will improve early detection of EOC and endometrial cancer 
(Paper 4). 
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Patients and Methods 
 
 
This section provides an overview of the patients and methods that were used in the 
thesis work. For a more detailed description, the reader is referred to the individual 
papers. 
 
This thesis was based on materials that were sampled in a multicenter study with the 
name Biomarkers of ovarian cancer (BIOMOVCA) (Papers I-III). It was a validation 
study built on a previous study performed by our group (121). The BIOMOVCA 
study was undertaken in collaboration with The Regional Cancer Center (RCC) West 
for ovarian cancers. Sampling of patients was done from September 2013 until 
February 2016 for Papers I-III, while for Paper IV the patient material was part of an 
international multicenter study conducted by Prof. B Vogelstein at Johns Hopkins 
University, Baltimore, USA. 
 
 
BIOMOVCA (Paper I-III)   
 
Study design   
This project was conducted in collaboration with the ovarian cancer group at the 
RCC West and all hospitals performing gynecological surgery in the Western 
Healthcare Region of Sweden and the county of Halland. Women were enrolled by 
both secondary (SKAS, SÄS, NÄL, Varberg, Halmstad) and tertiary (Sahlgrenska 
University Hospital) centers, prospectively and consecutively. Based on the study 
design, only patients from surgical units treating gynecological malignancies were 
included at Sahlgrenska University Hospital.  However, both malignant and benign 
cases were included from the secondary surgical centers. Women with highly 
suspected advanced ovarian cancer were referred to the tertiary center of Sahlgrenska 
University Hospital, according to the established practice and they were only entered 
once in the BIOMOVCA study. 
 
Power and group sizes were based on statistical estimations of results gained in a 
previous study performed by our group (121). Since the earlier study enrolled 
patients with suspected ovarian cancer that had been referred to Sahlgrenska 
University Hospital from specialized surgeons in gynecological oncology, they can 
be considered to represent a selected sample material. Therefore, the sampling 
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method used for BIOMOVCA was set out to secure a representative cohort of 
women, including women of all age groups and patients with benign lesions. For 
reference, approximately 21% of the patients entered into BIOMOVCA were 
diagnosed with malignant lesions as compared to roughly 15% (1 out of 7-10), which 
was suggested in the study by van Nagell et al. (77). In the Partheen et al. study, 30% 
of the women included were diagnosed with malignant lesions, while the study 
population of BIOMOVCA resemble a more “normal” population, in line with 15%. 
In Western Sweden around 600 patients are examined every year for suspected pelvic 
tumor/ovarian cysts. Based on previous experience we estimated that approximately 
150 of these 600 patients could be included in the BIOMOVCA study every year. 
This calculation gave us the estimated time for the trial of 2 years. Hence, the 
proposed group size was 300 patients and according to our calculations of power we 
planned for an interim analysis of our material after 150 patients had been enrolled. 
Importantly, all participating doctors at the different hospitals were informed about 
the details of the study and we obtained signed agreements for how to store and 
transport all sampled materials, including serum and base data sheets, as described 
in more detail in Paper I. Contact persons were identified at the different 
collaborating hospitals and these individuals were in continuous contact with the 
research group at Sahlgrenska, reporting on patient records for our coded 
registrations. In this way we could provide monthly updates on included patients 
made by the individual hospitals and reports were sent to all representatives in the 
RCC West Ovarian Cancer Group. The study was registered in the National Institute 
of Health clinical trial registry (ClinicalTrials.gov NCT03193671). 
 
Statistical considerations – establishing adequate sample sizes   
The first interim analysis of the data set was conducted in May 2014 with 158 eligible 
patients enrolled. The statistical evaluation was performed with ROMA and it gave 
a sensitivity (SN) of 91.7% (95% confidence interval 0.78-0.98). Based on the results 
a confidence interval (CI) of 0.83-0.97, was determined, i.e. a margin of error of +/- 
7.1%, when reaching a final sample size of 300. Hence, a sufficient SN was achieved 
but the CI was too wide. Therefore, if we enlarged the sample size to 400 
observations so the CI would become narrower with a margin of error of +/- 6%. We 
decided to perform a new interim assessment after an additional 150 patients and a 
total of 400 enrolled patients. The second interim analysis was conducted in January 
2015 with 319 observations. We found that the SN for ROMA was similar to the first 
analysis at 91.3% and with a CI 0.78-0.98, which still was too wide. The prevalence 
of EOC was 18% for the study population. We then extended our study to include 
over 600 patients, and at the end of 2015 we had collected the desired number of 
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entries and could close further inclusions into the BIOMOVCA study in late 
February 2016. In the final cohort, a total of 684 patients were enrolled and a 
prevalence of 21% EOC. 
 
Baseline data protocol   
The design of the study protocol was done in co-operation with the RCC West 
ovarian cancer group and the study section at the Department of Clinical Chemistry 
at the Sahlgrenska University Hospital. For each enrolled patient a unique code and 
baseline data sheet, reporting on lifestyle and health status parameters as well as 
information from the TVU examination and menopausal status, was obtained. The 
information was entered into an exclusive protocol registry (Figure 8). The same 
code was also used to tag the serum samples collected. All women were clinically 
assessed by a physician. TVU investigations were conducted by gynecologists under 
training as well as experts on gynecological ultrasound. 
 
 
Figure 8. Base data sheet. 
 
An exclusive protocol registry of lifestyle and biological parameters including menopausal 
status, entered for every patient included in the BIOMOVCA study and coded with a unique 
code. 
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Serum and tumor PAD samples   
All women included in this study received surgical treatment according to agreed 
clinical practice used at the local hospital, and enrollment into BIOMOVCA had no 
impact on the surgery performed. Serum samples were collected when patients were 
enrolled for surgery or at the time of admission and preoperative work-up. As 
indicated in Paper I, the coded samples collected at SKAS, SÄS and NÄL were 
shipped to the study section at Sahlgrenska University Hospital the following day for 
storage at -80 C°. Coded samples from Varberg and Halmstad were stored at the 
separate including hospitals, as described. Serum sample analysis was performed at 
the Department of Clinical Chemistry at the Sahlgrenska University Hospital and 
assessments of HE4, CA125, creatinine, and N terminal brain natriuretic peptide 
(NT-pro-BNP) were determined using the Cobas 6000 or 8000 instruments (151).   
 
Tissue biopsies were examined by an experienced pathologist for pathologic 
anatomic diagnosis (PAD), which included histological assessment and grading. All 
EOC PAD specimens were additionally screened by a pathologist specialized in 
gynecologic oncology at the Sahlgrenska University Hospital. Staging of tumors was 
done according to the recommendations given by the International Federation of 
Gynecology and Obstetrics (FIGO) 2014 standards (Figure 4). The correct cancer 
diagnose, grade and stage were obtained from the National Information Network for 
cancer treatment (INCA) and the information was entered into the BIOMOVCA 
registry.  Diagnoses of benign tumors were retrieved from the pathological reports 
entered into Melior or “vårdadministrativt system” (VAS), the hospital journal charts 
used in Western Healthcare Region and Halland, respectively. 
 
Analysis of biomarkers   
In earlier studies assessments of HE4 and CA125 have been done by enzyme linked 
immunosorbent assays (ELISA). This is a standard technology in clinical 
laboratories with a high acceptance and excellent reproducibility. However, it is not 
the most sensitive assay to determine proteins in biological samples. In 2010 FDA 
approved an automated HE4-assay based on electrochemiluminescence immune-
assay (ECLIA), to mitigate the shortcomings of ELISA. Determinations of CA125 
II, HE4, NT-pro-BNP and creatinine concentrations were therefore done on the of 
ECLIA Cobas 6000® or 8000®, e602 and e701 analyzer (Roche Diagnostics 
Scandinavia, Stockholm, Sweden). The ECLIA assay is a highly sensitive and 
specific method for assessing these proteins. Briefly, CA125 and HE4 were 
determined by two types of antibodies in combination with an electrode potential 
leading to a photon emission as visualized for HE4 in figure 9. The reference value 
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for a positive sample was set to >35 U/ mL for CA125 (90), and for HE4 we used 
predetermined thresholds >70 and >140 pmol/L for premenopausal and postmeno-
pausal women, respectively (152-154). 
 
PCR and NGS   
Polymerase chain reaction (PCR) and next generation sequencing (NGS) were used 
for identifications of mutations in gene sequences, as described in some detail in 
Paper IV. Briefly, whereas PCR is used to amplify or copy a specific DNA sequence, 
NGS can rapidly sequence the whole genome, or particular genes or target regions 
of interest. With NGS the targeted sequencing approach can include the genome (the 
protein-coding portion of the genome), specific genes or targets within genes or 
mitochondrial DNA. The NGS technology enables the search for rare mutations at 
large scale and provides unprecedented insights into how and when malignancies 
may occur in human cells. In fact, assessments of genetic and epigenetic mutations 
in tumor cells has greatly advanced cancer research, which is also seen in basic 
research on OC. The NGS technology will significantly contribute to the discovery 
of additional rare mutations and help in the early diagnosis of EOC. Because of the 
requirement of lower DNA input compared to previous technologies, NGS has 
enabled cancer research, were sometimes rare somatic mutations are present. Such 
as discovering residual tumor cells in the margins after surgery and monitoring 
effectiveness of cancer therapies by analyzing liquid biopsies for cancer cell gene 
signatures. Importantly, it will enable improvements in early detection of cancer, 
which for EOC is of outermost importance. 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. ElectroChemiLuminescence immunoassay (ECLIA) detection. 
Two types of antibodies were respectively used to make a “sandwich”: One antibody recognizing the 
analyte was labeled with ruthenium and the other with biotin. With the addition of streptavidin, then 
of tripropylamine (TPA) and the application of electrode potential, ruthenium was excited, leading to 
photon emission. (Illustration from Cobas Roche Diagnostics, with permission from Roche Diagnostics 
Scandinavia AB). 
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Pap smear and TAO brush sampling   
Pap smear test was initially invented by Papanicolaou in the 1920s and simplified in 
1957 by A Hilliard (155). It has revolutionized the prevention of cervical cancer 
throughout the world, where screening programs for cervical cancer are 
implemented. Incidence and mortality have been reduced by more than 75% (156). 
Since the traditional pap-smears have been replaced by a liquid-based method, the 
possibility for DNA detection as well as cytological analysis have been possible in a 
non-invasive easy-to-use test. Cells, not only from the cervix but also from the 
endometrium in the uterus cavity and the tubal lining including the ovaries, shed 
from the tumors via the tubes, and can be identified from samples taken from the 
cervix.  A previous pilot study, evaluated DNA collected from routinely taken pap 
smears. The results indicated a promising step towards a screening program for all 
gynecologic malignancies in the future with this method. With massively parallel 
sequencing, mutations in 100% of endometrial cancers and 41% of ovarian cancers 
were detected both in the tumor and the liquid Pap smear (157). As described, 
identification of tumor cells from other gynecological organs was made possible. To 
be able to get even closer to the original tumor, and in that way perhaps identify more 
tumor DNA, the TAO brush (The Indiana University Medical Center Endometrial 
Sampler) was used in this project (Paper IV). It was introduced as early as 1993 and 
approved by the FDA for general medical use. Initially it was used for endometrial 
sampling and cytology analyses of the brushing specimen from the endometrium 
(158). It has an outer sheet to avoid contamination from the vagina and endocervix, 
which is pulled back when applied in the uterus cavity. The brush is then rotated 360° 
counterclockwise for collection of DNA. The outer sheath is then pushed forward 
again and the TAO brush removed, and immediately placed in thin-prep buffers for 
disposal of DNA described above (Figure 10). 
 
 
 
 
 
 
 
 
Figure 10. Tao Brush™ IUMC Endometrial Sampler. A 3.5 cm long flexible brush that allows 
sampling from the endometrial cavity. A plastic sheet protects the brush from endocervical 
and vaginal contamination during insertion and extraction.  
(Illustration and permission from www.cookmedical.com/p/tao) 
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Here follows a short summary of the methods used in the individual papers that were 
discussed: 
 
 
Paper I   
 
In Paper I we included 638 patients selected from the cohort of 684 women using the 
exclusion criteria described in Paper I (Figure 11). Patients were categorized 
according to the diagnosis into three main groups; benign tumors (B), borderline type 
tumors (BOT) and malignant tumors (M). The M group was further subdivided into 
epithelial ovarian cancers (EOC) and a metastasis group, which consisted of non-
epithelial ovarian cancers (Non-EOC) and metastasis of non-ovarian origin to the 
ovary. The EOC group was subdivided into early (FIGO stage I+II) and late stage 
(FIGO stage III+IV) tumors, as well as type I and type II tumors according to the 
dualistic model. All women were classified into premenopausal (Pre-M) or 
postmenopausal (Post-M) status groups. Assessments of serum levels of CA125 and 
HE4, and calculations of RMI and ROMA were performed as described in detail in 
Paper I. 
 
In Paper I we used RMI 1, calculated according to the criteria described by Jacobs et 
al., whereas in Paper II we used RMI 3 calculations described by Tingulstad et al. 
(82, 83). The difference between the two algorithms is the value yielded by the 
ultrasound score. The ultrasound was evaluated according to 5 different parameters: 
multi-locular cyst, solid parts, bilateral cysts, presence of ascites and presence of 
intraabdominal metastases, and results in one point each. A unilocular cyst gives zero 
points in RMI 1, while in RMI 3 it will give a score of 1 (Figure 6). The different 
RMI calculations have been reviewed to compare the accuracy of the predictive 
models and it was found that the RMI 1 (Jacobs et al.) reached the highest sensitivity 
and specificity at cut-off 200 (159). The Swedish National Guidelines for OC 
diagnosis recommended RMI 1 at the time of writing Paper I (82). 
 
The statistical analyses were performed using STATA 13.1 (Stata Corp, Texas, 
USA). Categorical variables were presented as count and percentages, whereas the 
descriptive statistics were presented as median and range. Diagnostic performance 
was assessed by sensitivity (SN), specificity (SP), negative predictive value (NPV) 
and positive predictive value (PPV) for HE4, CA125, RMI and ROMA. Statistics 
were calculated for the individual groups subdivided for menopausal status 
accordingly; B vs EOC, B vs EOC+BOT, B vs EOC FIGO I+II (early), and B vs 
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EOC FIGO III+IV (late). Diagnostic accuracy was evaluated through receiver 
operating characteristics (ROC) and area under the curve (AUC) calculations. 
Statistical differences between groups for the separate markers were assessed using 
the Mann-Whitney U test. All tests were two-tailed and p-value <0.05 were 
considered statistically significant. We could have used a parametric test for 
calculating statistical significance in the main group B vs EOC, (without adjustment 
according to menopausal status), but the sub-groups were small and these data sets 
were skewed with mean > median values, which is why a non-parametrical test was 
chosen in all analyses. Whereas SN and SP are descriptors of the diagnostic ability 
of a test, they cannot directly indicate the probability if a patient is ill or not. Hence, 
it is critical with a high SN for OC patients as we want to find all cancer patients 
while a high SP, will help exclude healthy individuals. We therefore calculated the 
predictive values NPV and PPV, which are dependent on SN and SP as well as the 
prevalence of the disease. For diseases with a low prevalence, such as OC, a high SP 
is needed to maintain a high PPV, which is why PPV can be difficult to include as a 
predictor of OC. On the other hand, ROC AUC visualizes the proportion of true 
positives and the percentage of false positives in a diagnostic test at different 
thresholds. The challenge is to find a numerical threshold that gives a reasonable 
balance between high SN and low false positive results. In fact, this is the most 
common approach to evaluate the diagnostic ability of these types of tests. 
 
 
Figure 11. Flowchart of eligble patients for the BIOMOVCA study (paper I-III).  
 
Patients and Methods 
 
43 
 
Paper II   
 
The same study population and exclusion criteria were used as described for Paper I 
(Figure 11). The metastasis to the ovary group (n=25) and non-epithelial ovarian 
cancer tumors (n=2) were grouped together. Patients with EOC tumors were also 
subdivided according to molecular genetics and histopathological type I and type II. 
BOT, metastasis to the ovary and non-EOC tumors were analyzed in subgroups, as 
described in Paper II. RMI 3 was used according to Tingulstad et al., which was 
preferable from a statistical modeling perspective, as more patients will be included 
in the study (including women with a unilocular single-sided cyst), taking into 
account the expected  normal distribution of women with benign ovarian cysts. We 
used the R version 3.6.1 (R Core Team 2019). The aim of this study was to improve 
already established markers (RMI, ROMA and CA125) by combining them with 
HE4 or TVU. Logistic regression analysis was used since our primary response 
variable were binary (cancer/no cancer) and our data contained several outliers, not 
normally distributed. Three logistic regression models were fitted: RMI with the 
addition of HE4, ROMA with the addition of TVU score and the dual combination 
CA125 and HE4. RMI, CA125 and HE4 were log2-transformed before fitting the 
models to reduce the effects of extreme values. The benign and EOC samples were 
coded with a binary variable, where benign=0 and EOC=1 (cases).  
 
The algorithms were established according to the following template:  
 
Y=a+b1x1+b2x2 
 
The three new logistic regression models were named Gothenburg index (GOT)-1, 
GOT-2 and GOT-3 (Figure 12). 
 
 
 
 
 
 
 
 
Figure 12. Overview of the logistic regression models named Gothenburg index (GOT)-1, 
GOT-2 and GOT-3 established according to the following template Y=a+b1x1+b2x2. The 
intercept (a) was dropped for simplicity.   
GOT-1 = 0.62 x log2(RMI) + 1.05 x log2(HE4) 
GOT-2 = 0.59 x log2(CA125) + 1.31 x log2(HE4) 
GOT-3 = 7.02 x ROMA + 0.68 x TVU 
 
Patients and Methods 
 
44 
 
To investigate the performance of the new models for discriminating between 
benign-and EOC tumors, a target sensitivity (target SN) was calculated using the 
markers (RMI, ROMA, CA125) with established cut-off values (Paper II). From 
target SN, specificity (SP) and ROC AUC were calculated to determine the 
diagnostic capacity. Additionally, we used a target specificity (SP 75%) and 
calculated GOT 1-3 sensitivity in order to compare our results with other research 
groups in the field. A set SP of 75% is an often used SP for diagnostics, but an 
acceptance for as many as 25% false positive cases can be discussed (118, 160). 
 
The likelihood ratio test was used for comparison between GOT 1-3 and their 
baseline models. A p-value of <0.05 was considered statistically significant. 
 
Models were validated using leave-one-out cross fold validation, with the dataset of 
benign and EOC diagnosed women (n=580). Thus, the cohort was split into a training 
set and a validation set 580 times, with 579 samples in the training set and the 
remaining sample in the test set. Inside the cross-validation loop, the model was fit 
with the training set and evaluated on the test set. Performance of the model was 
calculated based on all 580 iterations, to obtain a realistic estimate of SN, SP and 
ROC AUC. 
 
Improving and exploring new and old algorithms can preferably be conducted on two 
separate study cohorts, using one for model preparation and one cohort for testing 
(external validation). However, since we only had one cohort for both model 
preparation and validation, we used leave-one-out cross validation to mimic external 
validation.  
 
 
Paper III   
 
The aim of this study was to examine how different lifestyles and biological factors 
impacted on serum levels of the biomarkers CA125 and HE4. For this purpose we 
used the benign cohort described in Paper I, consisting of 445 women diagnosed with 
a benign ovarian cyst (Figure 11). 
 
At the time for enrolment a base data sheet was compiled by the handling physician 
for each patient. The data sheet included information about age, smoking habits, 
weight, length, endometriosis, parity, hormone replacement therapy (HRT), renal 
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disease, heart disease, other cancer diseases and heredity for ovarian- and/or breast 
cancer (Figure 8).  
 
Body mass index (BMI) was calculated according to the standardized procedure, 
weight and length in the following formula kg/m2. As a measure of heart failure NT-
pro-BNP was analyzed. It is a natriuretic peptide that is released from the myocardial 
tissue as a result of myocardial wall extension.   
 
Estimated glomerular filtration rate (eGFR) is a measure of the glomerular filtration 
and refers to the amount of fluid that is filtrated from the glomerular capillaries to 
the tubuli system per minute in the nephrons. As a measure for renal failure, serum 
creatinine was analyzed and eGFR was calculated according to the revised Lund-
Malmö equation (161). With impaired renal function, eGFR will decrease. 
Commonly, normal renal function is associated to eGFR >90 ml/min/1.73. 
 
The descriptive statistics were presented as mean values and standard deviations 
(SD) as well as median values and range. Categorical variables were presented as 
mean counts and percentages. As in Paper II, statistical analyses were done with the 
R version 3.6.1 (R Core Team 2019). A multivariate logistic regression model was 
created to distinguish between false positives (FP) and true negatives (TN), predicted 
using CA125 and HE4 with established cut-off values. As described, odds ratios 
(OR) and the 95% confidence interval (95% CI) of predictors were calculated for the 
risk of being classified as a false positive by the marker. The following categorical 
predictors were included and dichotomized to fit the model: pelvic inflammatory 
disease (PID), endometriosis, HRT, smoking, other cancer diseases and heredity for 
ovarian- and/or breast cancer. The following continuous predictors were included: 
age, eGFR, NT-pro-BNP, BMI and parity. Overall, we identified missing data for in 
women of the 445 enrolled and of these were 61 missing heredity, four smoking and 
four other cancer diseases. All missing values were imputed as not present and 
replaced with 0=no. Whereas a linear regression model could not be applied to the 
data due to non-normal distribution, i.e even after log transformation as for HE4, in 
particular, we used logistic regression analysis. The likelihood ratio test was used to 
assess the statistical significance of the separate predictors. Benjamini-Hochberg 
correction was performed to adjust for multiple testing. Adjusted p-value of <0.05 
was considered statistically significant. Because of the logistic regression model 
approach, we were limited to examine only the change (increase or decrease) in 
serum biomarker levels relative to a threshold level, and not the actual concentration 
of the biomarker. However, the statistically significant predictors showed strong 
 
Patients and Methods 
 
46 
 
evidence for association. Noteworthy, imputing missing values as not present was 
considered reasonable, since the values were not listed in the base data sheet and 
therefore interpreted as not present. The results should be interpreted with some 
caution since, not finding an association does not mean that it does not exist. 
 
 
Paper IV   
 
This was an international multicenter study of women diagnosed with or suspicion 
of having EOC or endometrial cancer (EC), and was coordinated and executed by 
prof. Vogelstein. The cohort consisted of 1658 women and samples were collected 
and analyzed retrospectively at the Ludwig Center for Cancer Genetics and 
Therapeutics, at John Hopkins University School of Medicine, in Baltimore, USA. 
The patient material represented women attending gynecological clinics at six 
different centers, including three centers in the U.S, and one center in Canada, 
Denmark and Sweden, respectively. The sampling involved Pap-brush sampling 
from the cervix only at the different centers. One center in the US also sampled TAO 
brush specimens from the uterine cavity. This way cells or tumor DNA, not only 
from the cervix, but also from the endometrium in the uterine cavity, or from the 
tubal lining or the ovaries, could be sampled. Plasma was withdrawn prior to surgery 
in cell-free DNA blood collection tubes (BCT, Streck tubes 2189629), used for 
stabilizing nucleated blood cells allowing isolation of cell-free DNA (Figure 13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. PapSEEK tests for the detection of tumor DNA in the Pap brush, TAO brush and 
plasma samples.  
Wang et al., Sci. Transl. Med. 10, eaap8793 (2018). 
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All specimens were coded and stored at -80° before being shipped to the laboratory 
in Baltimore. Indeed, using this technique, a previous study has detected mutations 
in 100% of endometrial cancers and 41% of the ovarian cancers (157). The study 
also involved re-reviewing the tumor PAD by pathologists specialized in 
gynecological malignancies at the Baltimore center. 
 
Somatic mutation-specific detection and aneuploidy (PapSEEK)   
By using whole genome sequencing, mutations typical for the different histological 
subgroups of ovarian- or endometrial cancers can be detected (10). Hence, the NGS 
analysis in Paper IV was developed based on detection of mutations in selected genes 
(16 or 18 genes) as described in Table 2 (10, 157, 162). Countable mutations were 
identified on the basis of the following criteria: a) mutations were present in the 
COSMIC database of somatic mutations of human cancer cells (163) or b) nonsense 
mutations, out-of-frame insertions, splice site mutations or gene deletions that were 
located in tumor suppressor genes (163). To score positive, a sample had to be 
positive either for a somatic mutation (Safe-seq) or aneuploidy (Fast-seq), and was 
then given a PapSEEK positive score. Even if a test result was negative for a somatic 
mutation in any of the 18 genes assessed, the PapSEEK test could still be positive if 
aneuploidy was detected. COSMIC is a catalogue of somatic mutations, a high-
resolution resource in the genetics of human cancer (163). It encompasses all forms 
of human cancer, from large scale tumors to extremely rare variants. The database 
contains 1,235,846 tumor samples and 4,067,689 observed coding mutations 
(version 78, September 2016) (163). NGS have disadvantages and can therefore not 
be used in general to detect rare low-count variants due to the high error rate which 
occurs during the sequence process. DNA changes in the end product after 
sequencing may be a) errors that are introduced when the template of interest is 
produced, b) errors during the amplification step when the library are produced or c) 
errors during amplification in the instrument used. Compared to NGS, the Safe-seq 
technology (used on both Pap brush, TAO brush and plasma samples) has enabled 
more reliable sequencing data for the detection of rare mutations, which are typifying 
EOC. First a unique identifier (UID) is added to one primer in each pair in every 
DNA template to be analyzed. The UIDs consists of 14 degenerate bases with an 
equal chance of being an A, C, T or G. Secondly, amplification of the template of 
interest is carried out with the unique identifier to create many daughter molecules 
containing the identical sequence (called UID family). If a mutation is present in the 
template molecule, which was used in the amplification process, it should also be 
present in every daughter molecule containing that UID. An UID family where at 
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least 95% of the family members contain the identical mutation is called a 
supermutant (Figure 14) (164). 
 
Fast-seq is an amplicon-based approach for detection of aneuploidy. One single 
primer pair is used to amplify 38.000 long interspersed nuclear elements (LINEs) 
with PCR, where read depth at a locus is compared with the overall mean. The 
sequence data is analyzed with Within-Sample AneupLoidy DetectiOn (WALDO), 
which is an algortithm for amplicon-based aneuploidy detection. It incorporates a 
support vector machine (SVM), a learning model that categorizes samples as either 
aneuploid or euploid, using a non-probabilistic binary linear classifier (Figure 14). 
 
 
Table 2. Driver mutations evaluated for plasma, pap- and TAO brush samples.  
Driver mutations       
      
18 somatic mutations 
detection in Pap- and TAO 
brush samples 
Tumor specific 16 somatic 
mutations detection 
in plasma 
Tumor specific 
AKT1 EC AKT1 EC 
APC EC BRAF OC 
BRAF OC CDKN2A OC 
CDKN2A OC CTNNB1 OC, EC 
CTNNB1 OC, EC EGFR EC 
EGFR EC FBXW7 EC 
FBXW7 EC FGFR2 EC 
FGFR2 EC KRAS OC, EC 
KRAS OC, EC NRAS EC 
MAPK1 EC PIK3CA OC, EC 
NRAS EC PPP2R1A OC, EC 
PIK3CA OC, EC PTEN OC, EC 
PIK3R1 EC TP53 OC, EC 
POLE EC, OC GNAS OC 
PPP2R1A OC, EC HRAS EC, OC 
PTEN OC, EC NRAS EC 
RNF43 EC    
TP53 OC, EC     
 
Description of the somatic mutation detection for plasma and Pap- and TAO brush  
samples. Additionally a description for each mutation is stated for which cancer  
diagnosis they are most commonly found in.  
 
OC=ovarian cancer; EC=endometrial cancer 
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Figure 14. Illustration of the PapSEEK workflow.  
(Chloee2019/Wikimedia/CC BY 4.0/https://creative commons.org/licenses/by-sa/4.0/) 
 
 
The descriptive statistics of this study were presented as the mean with 95% 
confidence intervals (CI). The analysis was conducted using a median mutant allele 
fraction (MAF)-based approach. The distribution of mutations found in the control 
group was compared with MAFs of all mutations to perform a mutation-specific 
normalization. The MAF was defined as the ratio between the number of super-
mutants divided by the number of UIDs. By comparing the normalized MAFs of each 
mutation with a reference distribution of normalized MAFs, a p-value was 
calculated. Each sample was analyzed in two duplicate wells and assessed using 
Stouffer’s Z score method. The assumption (null hypothesis) on which the p-value 
(then transformed to a Z-score) was calculated for each well is that the well contains 
no driver mutations and only technical artifacts, which follow the reference 
distribution build from the normal controls. To compare the sensitivity of PapSEEK 
on tumor samples using either Pap-brush or TAO brush, a McNemar test was used. 
Ten-fold cross validation was used to calculate SN an SP for Pap- and TAO brush, 
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and plasma samples. Confidence intervals were calculated for SN and SP, assuming 
binominal distributions. A p-value of <0.05 was considered statistically significant. 
 
 
Ethical considerations    
 
Ethical approval was obtained for all four Papers in this thesis from the regional 
ethical committee at Gothenburg University. Paper I-III from ref: 139-13 and Paper 
IV from ref: 510-13. All participating women received written and oral information 
of the trials and had an opportunity to decline participation either directly or at any 
time after inclusion. 
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Results 
 
 
Study population in papers I-III   
 
A multicenter investigation of 684 patients was undertaken, out of which 638 were 
eligible and enrolled in the BIOMOVCA study (Figure 11). A total of 46 patients 
were excluded according to criteria agreed upon prior to initiation of the study. 
Thirtyfour women declined to participate, while eight women had serum sample 
collection failures, one patient refused to undergo surgery, two patients were entered 
twice at different hospitals, and one woman had neoadjuvant chemotherapy 
treatment prior to surgery. The distribution of the patients enrolled into BIOMOVCA 
is visualized in figure 15. The majority of patients were collected at the Sahlgrenska 
University Hospital and the regional hospital NÄL (70%). 
 
 
 
Figure 15. Included patients divided by benign (B), borderline (BOT) and EOC tumors (M) for 
the separate hospitals and units participating in the BIOMOVCA study (Paper I-III). 
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Subgrouping of the patients according to histology gave three main categories; 
benign (B), borderline type (BOT) or malignant EOC tumors (Figure 16). The 
distribution of EOC histology and stage is shown in figure 17. Noteworthy, women 
with the malignant EOCs, were 12 years older than the group with benign tumors, 
which was also expected since EOC is more common among older women. This fact 
also had an impact on the overall serum levels of HE4 and CA125, since HE4 values 
have been reported to be higher in post-menopausal women. 
 
 
Figure 16. Included patients divided by histology and benign (B), borderline (BOT) and 
EOC tumors (M) in the BIOMOVCA study (Paper I-III). 
 
 
Figure 17. Included patients diagnosed with epithelial ovarian cancer (EOC) divided 
by histology and stage in the BIOMOVCA study (Paper I-III).  
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Paper I   
The aim of Paper I was to validate the serum biomarkers CA125 and HE4 alone or 
in the context of the RMI and ROMA algorithms in an unbiased cohort of women 
diagnosed with ovarian cysts/pelvic tumors. The purpose was to find out whether any 
of these diagnostic procedures (HE4 and ROMA) could be recommended for 
implementation in routine pre-operative diagnostic assessments/triage of women 
with an ovarian cyst/pelvic tumor of unknown origin. 
 
All these markers were found useful for diagnostic purposes to discriminate patients 
with EOC from benign conditions in our cohort of unselected women diagnosed with 
an ovarian cyst/pelvic tumor. 
 
Statistically significant results were obtained for all assessments; i.e concentrations 
of HE4 or CA125 and the algorithms RMI and ROMA, enabling us to discriminate  
between benign from EOC, benign from EOC+BOT, benign from early stage EOC 
tumors (FIGO I+II), and benign from late stage EOC tumors (FIGO III+IV). No 
statistical significance was seen for HE4 assessments when comparing benign and 
BOT tumors in the postmenopausal group, or CA125 assessments in the 
premenopausal group. 
 
Comparison between benign tumors vs. EOC, showed that serum CA125 levels 
achieved the highest sensitivity in both pre- and postmenopausal women (95.7 Pre-
M; 92.0 Post-M). Assessments of serum HE4 levels was less predictive (82.6 Pre-M; 
72.3 Post-M) (Table 3). However, serum HE4 levels outperformed CA125 levels in 
specificity. CA125 gave 40.4% false positive assessments in the Pre-M group and 
20.5% false positives in the Post-M group, whereas HE4 determinations gave 9.1% 
false positives in the Pre-M group and 7.9% false positives in the Post-M group 
(Table 3). Thus, assessments of serum HE4 was superior to CA125 determinations 
in detecting healthy women. The algorithms assessed for triage of women, RMI and 
ROMA, were almost identical in their predictive ability for differential diagnostics 
(ROC AUC RMI Pre-M: 0.88, Post-M: 0.85; ROC AUC ROMA Pre-M+Post-M: 
0.84). These results support the notion that ROMA, which does not include TVU, 
could be recommended for general practice diagnostic work up when EOC is 
suspected as it only includes menopausal status and serum samples.  
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Table 3. Diagnostic ability for HE4, CA125, Risk of Malignancy Index (RMI), and Risk of 
Malignancy Algorithm (ROMA) comparing benign (B) disease with malignant (M) disease. 
 
EOC Pre-M (n=23) 
Diagnostic Test HE4  (>70 pmol/mL) 
CA125  
(>35 U/mL) 
RMI  
(>200) 
ROMA  
(≥11.4) 
SN 82.6 95.7 87.0 87.0 
SP 90.9 59.6 89.6 80.9 
ROC AUC (95% CI) 0.867  (0.786-0.950) 
0.776  
(0.723-0.829) 
0.883  
(0.810-0.956) 
0.839  
(0.764-0.914) 
PPV 47.5 19.1 45.5 31.3 
NPV 98.1 99.3 98.6 98.4 
EOC Post-M (n=112) 
Diagnostic Test HE4  (>140 pmol/L) 
CA125  
(>35 U/mL) 
RMI  
(>200) 
ROMA  
(≥29.9) 
SN 72.3 92.0 89.3 91.1 
SP 92.1 79.5 80.5 77.2 
ROC AUC (95% CI) 0.822  (0.777-0.867) 
0.857  
(0.820-0.895) 
0.849  
(0.810-0.888) 
0.841  
(0.803-0.880) 
PPV 82.7 70.1 70.4 67.5 
NPV 86.5 95.0 93.5 94.3 
 
M=epithelial ovarian cancer (EOC), SN=Sensitivity, SP=specificity, ROC AUC=Receiver Operating 
Characteristics area under the curve, PPV=positive predictive value, NPV=negative predictive value, 
Pre-M=premenopausal, Post-M=postmenopausal 
 
 
Paper II   
The aim of this study was to improve the diagnostic toolbox to better discriminate 
benign from malignant conditions in women with an ovarian cyst/pelvic tumor of 
unknown etiology. 
 
In Paper II three new models, GOT 1-3, were explored and compared with 
established diagnostic markers (RMI, ROMA, CA125) in an attempt to improve the 
ability to discriminate benign from malignant conditions in women with an ovarian 
cyst/pelvic tumor (Figure 12). 
 
The distribution of EOC according to stage and the dualistic model type I and type 
II are visualized in table 4. Ninety-nine patients (73.3%) were diagnosed with type 
II tumors and 36 (26.7%) with type I tumors. These results are in line with reported 
distribution of the dualistic model and indicates that the cohort reflects the common 
composition of tumors described in the introduction (33).  
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We found that all new models showed statistically significant improvements in their 
predictive ability as compared to the baseline models, p<0.001. The addition of 
serum assessments of HE4 to RMI (GOT-1) or CA125 (GOT-2) increased specificity 
(SP) to 86% and 79% (84% RMI; 68% CA125), at target sensitivity (target SN) of 
92 and 93%, respectively. A larger increase was seen in sensitivity (SN) at a set 
specificity (SP) of 75% for GOT-2 as compared to that observed with GOT-1. This 
effect could be explained by the already high sensitivity for the baseline model of 
RMI. The addition of TVU to the ROMA algorithm (GOT-3) improved specificity 
at target sensitivity for both pre-M (88%) and post-M (80%) patients compared to 
the baseline model of ROMA (81% Pre-M; 77% Post-M). At a set specificity of 75% 
the sensitivity increased for both pre-M and Post-M women. The addition of HE4 
assessments and TVU improved the diagnostic performance of both RMI and 
ROMA. The effect was especially pronounced after adding TVU to ROMA when 
the false positives were reduced for premenopausal women, as was the effect when 
HE4 assessments were added to CA125 assessments. 
 
In the subgroups analyses of the EOC group we divided the patients into early and 
late stage tumors and into type I and type II tumors. Whereas GOT-1 improved in 
specificity in both early (GOT-1 86%; RMI 84%) and late stage tumor groups  (GOT-
1 90%; RMI 84%), GOT-2 improved specificity for both early and late stage tumor 
groups, and additionally sensitivity, at a set specificity of 75%, for early stage tumors 
(SN GOT-2 85%; SN CA125 75%). The improvements for GOT-2 included 
improved diagnostic accuracy for early stage tumors (ROC AUC GOT-2 0.88; 
CA125 0.84), as well as late stage tumors (ROC AUC GOT-2 0.98; CA125 0.96). 
The results were similar when the analysis took into consideration the type I and II 
tumor subgroupings.  
 
A prior multicenter study modified the ROMA algorithm by adding age instead of 
menopausal status, Copenhagen Index (CPH-1) (165). This index is a modified 
regression model from an established algorithm as ours in Paper II.  Menopausal 
status was replaced by age due to the suggested correlation between elevated serum 
levels of HE4 and increased age, after the age of 50 (111, 114). To further analyze 
the possible comparison with alternative algorithms and marker tests from other 
groups CPH-1 was calculated for our cohort (not reported in Paper II). We calculated 
specificity (83%) as suggested by the authors, using the sensitivity (92%) at  
RMI >200 cutoff (as suggested by the authors), sensitivity (95%) and 75% specificity 
and AUC 0.95 (95% CI 0.93-0.97). The results of CPH-1 in our cohort were 
comparable with GOT 1-3 (Paper II).  
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Table 4. Epithelial ovarian cancer (EOC) classification according to histology, stage and 
dualistic model type I and type II.  
 
Histology Stage 
Grade  
Total  
n=135 (%) 
Lowgrade (G1) Moderate (G2) Highgrade (G3) 
Type I Type II Type II 
Serous (All) 
I 5   7 12 (8,9) 
II 3   9 12 (8,9) 
III 4 6 49 59 (43,7) 
IV 1   13 14 (10,4) 
Total   13 (9,6) 6 (4,4) 78 (57,8) 97 (71,9) 
Mucinous 
I 10     10 (7,4) 
II         
III 2     2 (1,5) 
IV         
Total   12 (8,9)     12 (8,9) 
Endometroid All) 
I 5 4 1 10 (7,4) 
II     1 1 (0,7) 
III     3 3 (2,2) 
IV   1   1 (0,7) 
Total   5 (3,7) 5 (3,7) 5 (3,7) 15 (11,1) 
Clearcell 
I 3     3 (2,2) 
II 1     1 (0,7) 
III 1     1 (0,7) 
IV         
Total   5     5 (3,7) 
Stromal 
I 1     1 (0,7) 
II         
III         
IV         
Total   1     1 (0,7) 
Undifferentiated 
I         
II     1 1 (0,7) 
III     1 1 (0,7) 
IV         
Total       2 2 (1,5) 
Carsinosarcoma 
I         
II     1 1 (0,7) 
III     2 2 (1,5) 
IV         
Total       3 3 (2,2) 
 
There were 52 women with early stage (FIGO I+II) disease and 83 women with late stage 
(FIGO III+IV) disease. 27% of the patients type I and 73% type II according to the dualistic 
model.  
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Paper III   
The aim of study III was to investigate the possible effect of different predictors on 
the serum markers CA125 and HE4 in the benign group. This was done to test the 
hypothesis that HE4 assessments could improve the diagnosis of women with a 
benign ovarian cyst. 
  
We selected and analyzed the benign cohort of the 445 patient cohort in 
BIOMOVCA. A total number of 137 patients (44 Pre-M; 93 Post-M) had false 
positive results with CA125 assessments and 38 patients (21 Pre-M; 17 Post-M) had 
false positive results with HE4 assessments (Figure 18). To reduce the proportion of 
women with benign cysts who undergo unnecessary surgery, and become subject for 
hormonal treatment due to castration, we investigated different possible confounders 
ability to give rise to a false positive result. 
 
In the multivariate logistic regression analyses, eGFR, as a measure of renal failure, 
and smoking were significantly associated with increased levels of HE4 in serum 
above the threshold value (adj p-value <0.001). NT-pro-BNP, as a measure of heart 
failure, was also significantly associated with an increased level of HE4 (adj p-value 
<0.05), but with an OR value of 1.0, indicating poor clinical relevance. Serum HE4 
levels increased with age, especially in postmenopausal women after the age of 50, 
which is in line with observations reported by other groups. Interestingly, age was 
not found to be a significant predictor in our multivariate regression model. 
Nevertheless, as there are two different cut-off values for HE4 assessments 
depending on the menopausal status our results were adjusted accordingly (>70 
pmol/L Pre-M; >140 pmol/L Post-M). The only predictor that was significantly 
associated with false positive CA125 levels was endometriosis (adj p-value < 0.001), 
confirming that endometriosis can bring about false positive results of CA125 
assessments (100, 103, 104). 
 
Additionally we explored the HE4 and CA125 predictors applied to different EOC 
histologies that lead to false negative results (tumors classified as benign). However, 
because of the few patients in this cohort we were unable to develop neither a linear 
nor a logistic regression model, for CA125 assessments. A total of 10 women (1 Pre-
M; 9 Post-M) had false negative results for the predictive value of CA125 and 35 
women for HE4 assessments, respectively (Figure 19) (4 Pre-M; 31 Post-M). 
Importantly, the demographics of the cohort was similar for patients with malignant 
EOC and benign conditions (Paper III) (Table 5). 
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Figure 18.  False positive (FP) results for HE4 and CA125 for the BIOMOVCA study (Paper I-
III). The results visualized according to menopausal status and histology. 
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Figure 19. False negative (FN) results for HE4 and CA125 for the BIOMOVCA study (Paper I-
III). The results visualized according to menopausal status and histology. 
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Table 5. Demographics of the study population with malignant disease. 
 
Biological and lifestyle 
factors 
Malignant EOC 
Pre-M (N) Post-M (N) Total N (%) 
Number of patients (N) 23 112 135 
Age (mean) 44.26 66.46 62.67 
BMI (mean) 27.08 26.37 26.49 
Smoking 5  11  16 (11.9) 
Heredity 3  8  11 (8.1) 
Other cancer disease 1  16  17 (12.6) 
Heart disease 2  32  34 (25.2) 
Kidney disease 1  4  5 (3.7) 
Endometriosis 4  7  11 (8.1) 
HRT 0  5  5 (3.7) 
Children (0) 7  13  20 (14.8) 
Children (1-2) 11  61  72 (53.3) 
Children (>2) 5  38  43 (31.9) 
 
Biological and lifestyle factors noted for the 135 women with epithelial ovarian cancer (EOC) 
diagnosis.  
 
N=number of women, children are denoted as 0=no children, 1-2=no more than 2 children, and 
>2=more than 2 children, BMI=Body Mass Index, HRT=Hormone replacement therapy, Pre-
M=Premenopausal, Post-M=Postmenopausal. 
 
 
The multivariate logistic regression model created for the malignant group had 
similar predictors as the model for the benign group (Table 6). Early stage disease 
(p-value <0.001) and other cancer diseases (p-value <0.01) were predictors 
statistically associated with false negative results of HE4 assessments. Increased 
knowledge about the diverse etiologies of EOC during the past decades has led to 
speculations as to how the different EOC histologies may affect the use of biomarkers 
for diagnosis. Unfortunately, the analysis could not be performed for CA125 due to 
the small group of only 10 women with false negative results. Mucinous histology 
was the only predictor that statistically could be linked to false negative results of 
serum HE4 determinations (p-value <0.001). For both the pre- and postmenopausal 
women with malignant disease included, median serum levels of HE4, when 
mucinous histology, was below cut-off (Pre-M 49.9; Post-M 75.2) (Table 7). 
Moreover, in false positive results, no association between different histologies and 
HE4 determinations was seen. For CA125 calculations, mucinous, serous, simple 
and stromal histology were all associated with a low risk of a false positive result. 
None of these histologies had a median concentration of CA125 above the cut-off 
for either pre- or postmenopausal patients (table 2, Paper III). 
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Table 6. Multivariate logistic regression analyses of different predictors for HE4 and CA125. 
 
Predictors HE4 CA125 
  OR 95% CI p-value 
adj  
p-value OR 95% CI p-value 
adj  
p-value 
Stage early 10.44 3.84 - 32.97 <0.001 <0.001 5.97 1.26 - 44.59 <0.05 0.254 
Endometriosis 3.44 0.69 - 19.33 0.133 0.292 3.82 0.39 - 31.72 0.229 0.562 
Age 1.00 0.94 - 1.06 0.922 0.922 0.98 0.91 - 1.07 0.664 0.664 
eGFR 1.45 0.53 - 4.19 0.474 0.579 0.37 0.07 - 1.89 0.227 0.562 
’NT-pro-BNP’ 1.00 1.00 - 1.00 0.198 0.363 1.00 1.00 - 1.00 0.605 0.664 
HRT 8.77 0.76 - 92.88 0.080 0.220 0.00 NA 0.416 0.562 
BMI 1.01 0.90 - 1.12 0.857 0.922 0.94 0.77 - 1.11 0.455 0.562 
Smoking 0.46 0.06 - 2.27 0.352 0.553 0.00 NA 0.117 0.562 
Children 1.54 0.98 - 2.51 0.060 0.218 1.30 0.66 - 2.67 0.444 0.562 
’Other cancer’ 8.41 2.31 - 35.55 <0.01 <0.01 0.46 0.02 - 3.04 0.460 0.562 
Heridity 2.12 0.25 - 13.19 0.455 0.579 0.00 NA 0.284 0.562 
 
Thirtyfive women (31 Pre-M; 4 Post-M) had false positive serum values for HE4 and 10 
women (9 Pre-M; 1 Post-M) had false positive serum values for CA125 when using 
established cut offs from the manufacturer. Multivariate logistic regression analyses were 
performed with different predictors for HE4 and CA125 separately. P-values were calculated 
and adjusted (adj p-value) for multiple testing with Benjamin-Hochberg correction.  
 
PID=pelvic inflammatory disease, eGFR=estimated glomerular renal filtration, NT-pro-BNP=N-terminal 
prohormone of brain natriuretic peptide, HRT=hormone replacement therapy, BMI=body mass index, 
OR=odds ratio, 95 % CI=95% confidence interval. 
 
 
Table 7. Serum levels for HE4 and CA125 according to EOC histologic subtypes. 
 
Histology N 
Age 
(mean) 
  HE4   CA125 
 Mean Std dev Median Range  Mean Std dev Median Range 
Pre-M             
Clearcell 3 37.7  157.3 29.3 169.0 124.0-179.0  256.0 149.3 180.0 160.0-428.0 
Endometrioid 4 47.75  568.3 655.5 357.5 58.2-1500.0  1075.8 1596.5 414.5 51.0-3423.0 
Mucinous 4 41.5  63.4 30.6 49.9 44.7-109.0  117.8 71.7 123.0 25.0-200.0 
Serous 12 45.7  567.6 510.3 395.0 108.0-1500.0  1701.3 1803.9 1134.0 139.0-5000.0 
Total 23 44.3  426.5 487.2 179.0 44.7-1500.0  1128.6 1564.1 261.0 25.0-5000.0 
Post-M             
Carcinosarcoma 3 68.7  543.8 828.1 66.8 64.6-1500.0  64.3 32.1 61.0 34.0-98.0 
Clearcell 2 57.5  317.2 349.1 317.2 70.3-564.0  61.0 0.0 61.0 61.0-61.0 
Endometrioid 11 70.4  464.0 395.2 414.0 53.7-1151.0  298.4 302.0 148.0 16.0-823.0 
Mucinous 8 65.4  77.9 23.3 75.2 43.9-124.0  77.5 42.2 72.0 29.0-134.0 
Serous 85 66.1  626.3 533.1 407.0 48.3-1500.0  1131.6 1557.1 529.0  9.4-6710.0  
Stromal 1 79.0  473.0 NA 473.0 473.0  5000.0 NA 5000.0 5000.0 
Undifferentiated 2 62.0  183.5 126.6 183.5 93.9-273.0  426.0 415.8 426.0 132.0-720.0 
Total 112 66.5   554.2 517.2 332.5 43.9-1500.0   948.7 1468.0 368.5 9.4-6710.0 
 
Serum levels presented as mean, std dev, median and range. 
N=number, Std dev=standard deviation, Pre-M=Premenopausal, Post-M=Postmenopausal 
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Paper IV   
The aim of the study was to increase the sensitivity for detection of ovarian cancers 
by screening for gene mutations and aneuploidy using genital tract and circulating 
DNA samples from 1658 patients in a multicenter trial. 
 
In total there were 1915 samples from 1658 women included in this multicenter trial. 
1002 healthy controls, 402 women with endometrial cancer and 254 women with 
EOC.  
 
Pap-brush samples of 245 women diagnosed with ovarian cancer were assessed, of 
whom 33% (CI 95% 0.27-0.39) were PapSEEK positive, including 34% early stage 
(FIGO I+II) and 33% late stage (FIGO III+IV). Of the 382 women with pap-brush 
samples diagnosed with endometrial cancer, 81% (CI 95% 0.77-0.85) were 
PapSEEK positive. Only 1.4% were PapSEEK positive in the healthy control group 
of 714 women. The fraction of mutations found in the primary tumors were higher 
in the endometrial tumors than in the ovarian 97% and 73%, respectively. 
 
TAO brush samples of 51 women diagnosed with ovarian cancer were assessed, of 
whom 45% (95% CI 0.31-0.60) were PapSEEK positive, 47% early stage (FIGO 
I+II) and 44% late stage (FIGO III+IV). TAO brush samples from 123 women 
diagnosed with endometrial cancer were evaluated and 93% (CI 95% 0.87-0.97) 
were PapSEEK positive. None of the 125 women in the control group had positive 
results. The fraction of mutations found in the primary tumor as well as in the TAO 
brush samples were higher in the endometrial cancer samples (97%) than in the 
ovarian cancer samples (53%).  
 
Since both Pap brush and TAO brush samples were collected further away from the 
primary tumor in ovarian cancer compared to endometrial cancer and the fact that 
there are sometimes anatomical disorders that prevent testing for mutations with Pap- 
and TAO brushes, the hypothesis of detection of mutations in circulating tumor DNA 
(ctDNA) from plasma were tested in 83 women diagnosed with ovarian cancer. 
Primers were designed for shorter DNA fragments within 16 genes, due to the 
fragmented and small size of the ctDNA. The assay were additionally tested on 192 
healthy controls, with a specificity of 100%. Sixteen of these women had detectable 
mutations in the pap brush sample, 19 had a detectable mutation in their ctDNA and 
17 had detectable mutations in both pap brush samples and ctDNA. In total 63% of 
the 83 women assessed were positive for either of the two (Pap-brush or plasma) 
tests. 
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The specificity of PapSEEK for both Pap- and TAO brush samples were very high, 
resulting in few false positive results, indicating the high precision in ruling out the 
true healthy cases. The most commonly mutated genes found using Safe-Seqs with 
Pap brush were PTEN (64%), TP53 (41%), PIK3CA (31%), PIK2R1 (29%) and  
KRAS (18%) for endometrial cancers. TP53 was the most common mutation found 
for ovarian cancer for both pap brush samples (74%) and TAO brush samples (86%), 
which is consistent with previous studies of EOC and HGSC (10). 
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General discussion 
 
 
Methodological considerations   
 
A major strength of this thesis work is the multicenter approach. To avoid 
recruitment of patients only from tertiary centers, we turned to the different hospitals 
in the Western Region of Sweden and asked for their participation. This strategy was 
used to reduce the number of cases with advanced ovarian cancer disease (tertiary 
center population), and to include a more unbiased cohort of patients with an ovarian 
cyst/pelvic tumor. Although centralization of patients with advanced disease to 
tertiary centers has improved survival and success of surgical interventions, the 
tertiary center patients poorly reflect a normal distribution of women identified with 
ovarian cysts or symptoms of pelvic tumors (147, 149, 150). It is particularly 
important to evaluate new diagnostic tools in the context of what a first line screening 
can do to predict ovarian cancer. Assays with high specificity are critical in the 
selection of women in need of advanced surgery (149, 150). Moreover, a diagnostic 
tool should have a predictive value based on high sensitivity to avoid false negative 
cases, but equally important high specificity to minimize the number of false positive 
cases. Our aim was to investigate established diagnostic tools/criteria in an unbiased 
cohort and to calculate if we could improve the predictive value of the diagnostic 
tools in such a setting. Advanced operative cases are often few at small hospitals and 
patients with benign cysts are less frequent at tertiary centers. We planned to 
undertake a study that included all first line clinics to allow us to calculate predictive 
values of different diagnostic approaches in an unbiased cohort of women with 
ovarian cysts or suspected pelvic tumors. Only a few prior studies have used a similar 
clinical setting (Table 8 and 9) (118, 120, 160, 166-170) . 
 
Random errors   
Random errors affect precision of a result. Sample size is an important factor to 
consider when statistical uncertainty and random errors should be reduced. A larger 
sample size decreases statistical uncertainty and improves precision. This approach 
allows us to analyze random samples and obtain confident estimates based on the 
sample. This means that the target population, must have been given the opportunity 
to be selected. One way to adjust for or avoid random errors is to conduct sample 
size calculations, to predict if the sample size is big enough to test a statistical 
hypothesis.  
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For example, this is applicable when confidence intervals (CI) are calculated to 
describe the random error and to calculate the margin of error. With a larger sample, 
and a narrower CI the statistical uncertainty will decrease. During the present trial 
two interim analyses were conducted to assess whether a sufficient sample size had 
been obtained to allow for a reasonable CI. As the margin of error was considered 
too high and the CI too wide in the interim analyses, the sample size was extended 
from 300 observations to 684. A wide CI means a lower precision. In Paper I-IV the 
level of confidence was set to 95%. 
 
Systematic errors   
Systematic errors or biases are not affected by sample size but instead takes into 
account study design, analysis and data collection. It can be divided into three types: 
selection bias, information bias and confounding elements. These can arise during 
the planning of the study or during the implementation of the trial. These factors can 
introduce non-random errors to the study result and might lead to incorrect 
conclusions.  
 
Selection bias   
A selection bias is introduced when the sample is distorted and does not reflect the 
actual intended target population (171). Paper I-III were conducted on the same 
patient cohort from a large multicenter trial. Paper IV was based on a large 
international multicenter trial. In Paper I-III there was a discrepancy between the 
expected and the actual contribution of patients from the different centers (Figure 
15). Therefore, some women were diagnosed with an ovarian cyst but not enrolled 
for the study, potentially creating healthcare access bias. Another potential bias is 
when a patient enrolled at one hospital, but actually belongs to another hospital and 
community. This could create a selection bias, since the sample does not represent 
the actual population you aim to study. One way to avoid this type of selection bias 
could be to determine the number of patients that each unit should include prior to 
start, but in the present trial this was not done. In the earlier study the incidence of 
EOC was higher (30%) than in the present study (21%) and a majority of the women 
included in that study were postmenopausal and included at the tertiary center (121). 
This discrepancy gave a less representative sample and formed the basis for the 
decision not to determine the number of patients included at the separate units. It 
further reflects a filter referral bias addressing different levels of complexity in 
healthcare: from primary, secondary to a tertiary level (172). Inclusion of all patients 
from all different health care levels, as was done in the present study (Paper I-III), 
could be a way to mitigate this type of possible selection bias. Data collected for 
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clinical evaluation in a multicenter setting should be preferred over single center 
patient inclusions since the sample selection and size become more generalizable. 
 
Information bias   
An information bias occurs when improper data are introduced during the inclusion 
phase. For instance, if the time between inclusion and the time of surgery is too long, 
the disease can become more advanced, and the assessment with TVU and serum 
samples may no longer accurately reflect the diagnosis. In the present trial the study 
setup guaranteed that the time until surgery was as short as possible. A median of 6 
days (mean 14 days) was observed between clinical assessment, serum collection 
and time of surgery. Another bias regarding information is the fact that many 
individuals, e.g. patients, doctors and nurses, were involved in the inclusion 
procedure. The potential diverse degree of urgency depending on the individuals’ 
interest to participate in the study, may have affected the inclusion (Paper I-IV). An 
important question is whether all women eligible to be enrolled in the study received 
the same and correct information. It can be speculated that this might have been the 
reason why 34 women declined participation (Paper I).   
 
Another type of information bias is underreporting bias. All base line data of the 
participating women were recorded at the time of inclusion and not afterwards, to 
avoid recall bias. In the present trial several examples of when information bias can 
be introduced exist. For example, body weight and height figures are often not 
reported accurately due to concern about personal weight or height. At the time of 
inclusion all patients were asked to step up on the scale to avoid this type of bias.  
 
Smoking is another example when people tend to state “no smoking” since they 
might be embarrassed to tell the truth. In total, there were 95 women that stated that 
they were smokers in the cohort out of 638 women. It is thus difficult to know if the 
remaining women were truly non-smokers, but statistically 11% of the female 
population in Sweden are smokers (173), which is comparable to figures in Paper III 
in which 15% stated that they were smokers.  
 
Endometriosis is a PAD verified diagnosis, but several women might assume they 
have endometriosis due to discussions with their gynecologist on this topic, e.g. due 
to severe dysmenorrhea. For Paper I-III all reported endometriosis were PAD 
verified to avoid bias, either noted in the PAD report for the present surgery or found 
in the medical chart from previous surgery (Paper III). Eight women without PAD 
verified endometriosis were excluded from the group endometriosis.   
 
General discussion 
68 
 
There could have been mistakes in the classification of EOC when PAD diagnosis 
was set if the microscopy was performed by different pathologists, as several 
different molecular and histopathological features apply to the EOC diagnosis. 
However, to limit this bias all the EOC patients had their PAD re-reviewed by 
pathologists specialized in gynecological malignant diseases. 
 
Confounders   
A confounder is a variable that causes an inaccurate association between a dependent 
and independent variable. This situation can occur if the different groups studied lack 
comparability e.g. in terms of socioeconomic status, group size, age and gender. Such 
factors that can be assumed to affect the outcome. None of the studies in this thesis 
had matched controls, why this phenomenon might occur and may be considered a 
limitation in the study setup. In Papers I-III, the women with benign ovarian cysts 
were used as a control group, but they were not matched with the groups with cancer 
diagnosis (EOC). The same comparisons were chosen in Paper IV, where the healthy 
controls were women with a benign condition and not linked to the cases with 
malignant disease, but included in the study for the same purpose as the women with 
cancer.  
 
This study setup was chosen (Paper I-III) since ovarian cancer is a rare disease. By 
choosing the multi-center study setting, we aimed to avoid a skewed distribution 
regarding age and diagnosis. In Paper III, we adjusted for confounders and evaluated 
the associations between different variables and the outcome. 
 
A challenge when creating a multivariate logistic regression model is to decide which 
predictors to include, since too many predictors will result in less statistical power. 
For that reason, we chose to include the lifestyle and biological factors noted for each 
patient in Paper III. These parameters were the main factors we wanted to analyze. 
Endometriosis and pelvic inflammatory disease (PID) were the only histological 
predictors included, since there exists a strong relationship between ovarian cancer 
and these variables as reported by several groups (17, 51-53).   
 
There is always a risk that the predictors or variables excluded for the logistic 
regression analysis will affect the outcome of the analysis, such as the variables 
chosen. The aim was to test if the variables included actually had an impact on the 
outcome.  
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External and internal validity   
With external validity we imply whether results obtained are generalizable. This is 
dependent on the degree of internal validity of the results (174). The calculation of 
statistical power was conducted before the onset of the study (Paper I-II) and we 
tested benign tumors vs. all cases of EOC based on data reported in a previous 
publication (121). When comparing these groups in Paper I and II, we assumed that 
the multicenter trial would include a large sample and because of these results would 
also be generalizable. For subgroup analyses the internal validity was low, due to the 
small sample sizes, and this represents a limitation in the thesis. Nevertheless, the 
results obtained in our study are of great importance and lends support to similar 
results previously reported. Noteworthy, conducting a multicenter trial without 
hampering or changing the routine treatment protocol, as for example according to 
national guidelines, could be difficult. Inclusion of a control group of healthy women 
without any history of an ovarian tumor to our study could have decreased the 
possible selection biases for Paper III. For Paper I and II, on the contrary, this would 
not have been of value since these studies evaluated the performance of the 
biomarkers for possible clinical diagnostic applications.  Including a separate group 
of healthy controls in Paper IV could have been favorable, since screening for cancer 
was the intended use of the test. Another factor of value could have been to calculate 
how many patients each participating center could contribute with, to avoid selection 
bias. 
 
Another important threat to external validity is the complexity of the model created 
and the risk for overfitting the model and available sample. In Paper III we chose the 
lifestyle and biological factors, which is one way to avoid overfitting as described 
under confounders. In Paper II we conducted both model preparation and validation 
on the same cohort. This could be a threat to external validation, but to prevent that 
we used leave-one-out cross validation to mimic external validation. Not having an 
external cohort to conduct validation of the model can be seen as a limitation. 
Another important consideration is the interaction among variables. The effect of one 
variable on the outcome, such as positive cancer diagnosis, may depend on the value 
of another variable (175). In Paper III for instance, renal failure was found to be 
associated with elevated serum levels of HE4, thus implying false positive cancer 
diagnosis. Renal function decreases by age, and age was found to be associated with 
increased HE4 levels. Thus, these two variables might interact, increased age and 
decrease renal function, and can affect serum levels of HE4. This will further be 
important if HE4 measurements are used to determine treatment response in 
chemotherapy. Chemotherapy is filtered by the kidneys and decreases renal function. 
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Therefore, elevated HE4 levels for a postmenopausal woman treated with 
chemotherapy for an EOC tumor may not be a sign for either treatment response 
failure or relapse rather than the age or chemotherapy dependent effect on the renal 
function (111, 176). 
 
 
Discussion and future perspectives   
 
In this thesis we have validated assessments of the biomarkers HE4, CA125, and the 
algorithms RMI and ROMA, in a cohort of women investigated for an ovarian 
cyst/pelvic tumor of unknown origin. The study specifically addressed the diagnostic 
success of these parameters to identify women with an early stage malignant disease. 
In addition the correct referral of patients with a suspected malignant disease, and 
the ability to distinguish them from benign conditions, was studied. To secure an 
unbiased approach we collected patients attending all gynecological clinics in 
Western Sweden. These women were considered to represent the normal population 
of women diagnosed with an unknown ovarian cyst/pelvic tumor (Paper I). 
Furthermore, our aim was to investigate whether combinations of biomarkers and 
algorithms could significantly improve specificity and sensitivity of diagnostic 
evaluation and improve differential diagnosis of patients with ovarian cysts/pelvic 
tumors (Paper II). A scoring system with too many false positive samples would 
negatively affect the credibility of the diagnostic accuracy as too many benign 
conditions would be selected for surgery. Our ambition was to increase specificity of 
the diagnostic toolbox. However, equally important was that we could justify 
reasonably good sensitivity of the diagnostic arsenal since a low sensitivity would 
miss patients in need of surgical interventions. In addition, confounding factors may 
influence the level of biomarkers in serum and, hence, indirectly contribute to poor 
diagnostic accuracy of the serum concentration assessed. Therefore, we investigated 
different predictors to increase the clinical validity of the diagnostic assessments in 
a subgroup of women with benign conditions (Paper III). Importantly, not all EOC 
subtypes develop large tumors accessible with imaging techniques, such as TVU, for 
diagnosis. The most common EOC subtype, HGSC, most often originate from the 
fallopian tube. It evolves from several microscopic small changes that are difficult to 
detect before they develop into advanced disease. Accordingly the need for 
alternative diagnostic methods are entitled.  In the final paper, we look into future 
perspectives to improve clinical diagnosis by employing genetic markers strongly 
linked to cancer. 
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Together with a group at Johns Hopkins University Hospital in Baltimore, USA, a 
multicenter analysis investigated whether mutations typifying EOC could be used to 
arrive at a diagnostic toolbox with sufficiently high predictive value to better serve 
the need for accurate diagnosis in women with ovarian cancer. Today we consider 
EOC quite an heterogenous group of diseases. Knowledge about EOC-specific 
mutations and access to an easy screening system of DNA in liquid biopsies taken 
from the genital tract or as a simple blood test from women with pelvic tumors, would 
greatly improve early diagnosis. This might help to limit the number of patients that 
unnecessarily undergo surgical interventions, while having a benign condition (Paper 
IV). At the same time molecular investigations will hopefully also lead to a better 
understanding of the etiology of EOC. Altogether, progress in this field will not only 
improve differential diagnostics, but also enable personalized treatments and 
therapies. 
 
Are serum HE4 levels or the ROMA algorithm a diagnostic instrument ready 
for clinical implementation?   
Early detection of EOC and an improved diagnostic specificity to avoid unnecessary 
castration of fertile women is of critical importance to increase survival rates and 
limit morbidity of unnecessary surgery in benign conditions. In recent years, a 
plethora of biomarkers and algorithms, as well as various combinations of these have 
been investigated to improve diagnosis of EOC (Table 8 and 9). To evaluate the 
possible use of serum HE4 determinations and the ROMA algorithm in everyday 
clinical practice, we evaluated samples from an unselected population of women 
diagnosed with ovarian cyst/pelvic tumor. Whereas we specifically wanted to 
evaluate HE4 and ROMA´s validity as diagnostic predictors that could improve early 
diagnosis of EOC in clinical practice, several previous studies have addressed this 
question, but used either a pre-set specificity and/or sensitivity (75-95%) of HE4 
levels (Table 8)(117, 120, 152, 160, 166, 177). Yet other studies have analyzed the 
biomarkers on different analytical platforms with different cut-off levels (74, 118, 
119, 178-180). In this study we defined clear criteria for eligibility, selected methods 
for recruiting patients and used an automated analytic platform with cut-offs 
recommended by the manufacturer, in a multicenter setting. 
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Table 8. Overview of studies evaluating the diagnostic performance of HE4, CA125, RMI and ROMA, comparing benign and malignant EOC cases. 
 
Cases   Study 
design 
Center Cut-off 
HE4 
SN 
(CA125/HE4/RMI/ROMA) 
SP 
(CA125/HE4/RMI/ROMA) 
SET SP 
(75%/90%/95%) 
ROC AUC 
(CA125/HE4/RMI/ROMA) 
Plattform 
CA125/HE4 
HP Year Author 
374  P S   81.6/78.1/NA/NA 80 (CA125) 75 (HE4) 0.87/0.84 Architect/ 
Fujirebio 
T 2011 Partheen et al. 
387  P M 150 87.0/65.2/NA/87.0 68.3/98.5/NA/86.1   NA Abbott/ 
Fujirebio 
T 2016 Romagnolo et al. 
128  P S 70 70.4/79.6/63.0/74.1 74.2/66.7/92.4/75.8   0.80/0.78/0.86/0.82 Roche/ 
Fujirebio 
  2012 Anton et al. 
50  P S 70/140 NA NA   0.61/0.76/0.69/0.74 Abbott T 2015 Richards et al. 
180  P S 140 86.2/86.2/NA/93.1 78.9/87.4/NA/90.7   0.91/0.92/NA/NA Roche T 2014 Ortiz-Munoz et al. 
361  P S 70 Pre: 91.0/84.0/66.0/84.0 
Post: 91.0/91.0/68.0/91.0 
Pre: 62.0/100.0/75.0/100.0 
Post: 65.0/96.0/58.0/77.0 
  Pre: 0.93/0.95/0.91/0.95  
Post: 0.90/0.96/0.89/0.95 
Abbott T 2014 Stiekema et al. 
1218  P S   91.7/91.3/96.0/94.8   75 0.93/0.94/0.96/0.95 Abbott T 2012 Karlsen et al. 
260 P S 70/140 86.4/69.7/80.3/87.9 52.7/86.0/79.6/68.8   0.82/0.84/0.88/0.89 Roche T 2015 Yanaranop et al. 
374  P S   NA/NA/76.0/84.7 NA/NA/92.4/76.8   NA/NA/0.93/0.89 Fujirebio T 2012 Van Gorp et al. 
213  P S 70 79/71/77/75 62/90/82/88   0.81/0.82/0.85/0.84 Abbott   2016 Al Musalhi et al. 
160  P S 70 69.0/86.2/NA/89.6 90.1/85.9/NA/87.3   0.89/0.91/NA/0.93 Fujirebio T 2011 Jacob et al. 
233  P S   61.2/77.6/NA/NA   90 0.84/0.91/NA/NA Fujirebio T 2008 Moore et al.  
784  P M   Pre: 95/75/90/80  
Post: 80/82/84/86 
  75 Pre: 0.80/0.76/0.82/0.77  
Post: 0.82/0.79/0.85/0.84 
Fujirebio   2018 Liest et al. 
531  P M   NA/NA/NA/88.7 NA/NA/NA/74.7   NA Abbott/ 
Fujirebio 
  2009 Moore et al.  
457  P M   NA/NA/84.6/94.3   75 NA/NA/0.87/0.95 Abbott/ 
Fujirebio 
  2010 Moore et al.  
151  P S 37 CA125/ 
30 HE4 
83.0/98.0/NA/NA 100/100/NA/NA   0.91/0.99/NA/NA Liaison/ 
Fujirebio 
T 2009 Montagnana 
225  P M   78.6/78.6/NA/NA   95 0.92/0.96/NA/NA Fujirebio   2009 Huhtinen 
389 P S 70 79.5/74.5/NA/84.9 81.6/83.3/NA/79.7  0.88/0.86/NA/0.90 Fujirebio T 2011 Van Gorp et al. 
419  P S 70/140 Pre: 92.3/84.6/NA/84.6  
Post: 94.3/78.2/NA/93.1 
Pre: 59.4/94.2/NA/81.2  
Post: 82.3/99.0/NA/84.4 
 NA Abbott T 2011 Bandiera 
1590 P M  Post: 66.7/53.8/64.1/69.2  90 0.85/0.80/0.86/0.85 Roche  2020 Gentry-Maharaj et al. 
 
EOC=epithelial ovarian cancer; ROC AUC=receiver operating characteristics area under the curve; P=prospective; S=single center; M=multi center;  
SN=sensitivity; SP=specificity; HP=high-risk population: T=tertiary center; NA=not applicable
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As described in this thesis, EOC is often diagnosed at a late stage. This is often due 
to the asymptomatic nature of EOC at the early stages. Thus, when a woman is 
investigated for an unknown pelvic tumor it is of great importance to correctly 
identify malignancies, while securing that no false positives are registered. In this 
way we can improve the decision of which patients should be referred to a tertiary 
center for further investigations. At present, the Swedish Western Health Care 
Region (WHCR) consensus is to assess serum levels of CA125 together with 
imaging techniques including either TVU by a gynecologist with variable 
experience, CT scan or MRI. Investigations of a suspected pelvic tumor should be 
undertaken according to the guidelines recommended by the “national health care 
program”. These include TVU assessments for RMI, or the pattern recognition 
protocol or the more subjective IOTA simple rules (181). Neither serum levels of 
CA125 nor the RMI algorithm alone carry a sufficiently high predictive value for 
the diagnosis of EOC, and therefore we investigated whether serum assessments of 
HE4 or ROMA would be better from a diagnostic perspective. Several studies prior 
to ours have validated the diagnostic ability of serum assessments of CA125 and 
HE4, as well as employed the RMI and ROMA algorithms. Surprisingly, many 
have evaluated these parameters only in a high-risk population linked to a tertiary 
center (Table 8 and 9). This implies a highly selected population with dominance of 
elderly women (above 60 years), as these are overrepresented in EOC (74, 121, 
165, 178, 179). Women with less advanced tumors may therefore not be included 
in these settings. It is important to thoroughly validate the diagnostic value of new 
biomarkers and algorithms in the regional setting before implementing them into 
clinical practice. 
 
We found that serum CA125 levels showed the highest sensitivity (Pre-M 95.7; Post-
M 92.0) and HE4 levels the highest specificity (Pre-M 90.9; Post-M 92.1) in 
discriminating EOC tumors from benign tumors (Paper I). These results agree well 
with findings reported by other groups, albeit they were smaller, and trials that have 
used recommended cut-off values (180, 182-184)(Table 8). Moreover, we found that 
the combination of serum levels of both CA125 and HE4 in the new algorithm GOT-
2 improved specificity from 68% (CA125) to 79%, which confirms what has 
previously been proposed (ref partheen, moore). We believe that the addition of 
serum levels of HE4 is the single most important parameter to improve today’s 
diagnostic arsenal based on CA125 assessments, and RMI or ROMA algorithms 
(Paper I-III). HE4 assessments should, therefore, be implemented in clinical practice 
when investigating women for a possible EOC.     
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Table 9. Overview of studies evaluating different multi-marker tests and different algorithms, comparing benign and malignant EOC cases. 
 
Test Cases  Study 
design 
Center FDA Panels of biomarkers Subject 
characteristics 
SN SP SN 
SP 75% 
ROC 
UAC 
Platform HP Year Author 
MIA  
(OVA1) 
524  P M Y CA125, beta 2 
microglobulin, TRF, 
transthyretin, 
apolipoprotein A-1 
NA 93.0 43.0   Roche/Siemens 
Healthcare 
Diagnostics 
 2011 Uueland 
MIA2G 
(Overa) 
493  P M Y CA125, HE4, FSH, TRF, 
apolipoprotein A-1 
NA 91.3 69.1   0.92 Roche   2016 Coleman 
ROMA-P 413  P S   HE4, CA125 Age 85.0 98.0   0.92 Roche/Abbott T 2016 Chudecka Glaz 
CPH-1 1610  P M   HE4, CA125 Age 82.0 88.4 90.6 0.93 Roche/Abbott/ 
Fujirebio 
T 2015 Karlsen 
ROMA 531  P M Y HE4, CA125 Menopausal status 88.7 74.7     Abbott/Fujirebio  2009  Moore 
R-OPS 266  P S   HE4, CA125 TVU, Age 93.9 79.9   0.95 Roche T 2016 Yanaranop 
RMI I 143  P S   CA125 TVU, menopausal 
status 
85.4 96.9     Abbott   1990 Jacobs 
RMI II 173  P S   CA125 TVU, menopausal 
status 
80.0 92.0     Abbott   1996 Tingulstad 
RMI III 365  P M   CA125 TVU, menopausal 
status 
0,71 0,92     Abbott   1999 Tingulstad 
Multimarker 184  P S   CA125, HE4, YKL-40, 
transthyretin, ApoA1, 
beta-2-microglobulin, 
transferrin, LPA 
NA 94.0 76.3   0.83 Abbott T 2019 Moore 
ROCA 6532 RCT M   CA125 TVU  99.8   0.93 Centocor   2005 Menon 
Triple screen 218  P S   HE4, CA125 Symptom index 79.0 91.0     Achitect T 2017 Goff 
Symptom 
index 
607  P M     Pelvic/abdominal 
pain, increased 
abdominal size 
/bloating, difficulty 
eating/feeling full 
<50 years: 
86.7; >50 
years 66.7 
<50 years: 
86.7; >50 
years: 90 
    NA   2006 Goff 
EOC=epithelial ovarian cancer; ROC AUC=receiver operating characteristics area under the curve; P=prospective; RCT=Randomized controlled trial;  
S=single center; M=multi center; FDA=US Food and drug administration; SN=sensitivity; SP=specificity; HP=high-risk population: T=tertiary center; 
NA=not applicable; Y=yes 
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Protein-based algorithms and multimarker tests   
Over the past decades a number of different protein-based algorithms and 
multimarker tests have been identified and tested, in an attempt to improve early 
detection of EOC and facilitate referral of patients with malignant disease (Table 9). 
Despite extensive evaluations of diagnostic parameters based on single markers, 
algorithms or combinations in multimarker tests, none of these have received the 
widespread acceptance for early detection of EOC. 
 
In Paper I, both RMI and ROMA were comparable in their diagnostic accuracy in 
discriminating EOC from benign tumors. As ROMA does not require advanced TVU 
it can be argued that ROMA should be preferred over RMI in the first line of clinical 
primary care. This allows referral of patients to tertiary centers or a gynecologist for 
TVU assessments (RMI), or assessments with any of the IOTA certified algorithms 
introduced (185-188). However, in our study ROMA did not outperform RMI as 
other groups have reported (160, 180). We rather found that both the ultrasound 
assessments, by any gynecologist at hand, and the addition of HE4 levels, 
significantly improved the differential diagnostic potential (Paper II). In our models 
we have, therefore, added either HE4 assessments or the TVU score to RMI, CA125 
or ROMA determinations. The results of Paper II pointed to only a slightly increased 
diagnostic accuracy (ROC AUC) in discriminating benign from malignant tumors; 
GOT-1 0.95 vs RMI 0.95; GOT-2 0.94 vs CA125 0.92; GOT-3 0.94 vs ROMA 0.93. 
Nevertheless, these results were calculated using established cut-off levels and 
clearly showed that the addition of HE4 improves specificity for both RMI (84% 
RMI; 86% GOT-1) and in particular for the specificity of CA125 assessments (68% 
CA125; 79% GOT-2). These improvements were higher for CA125 assessments 
alone with regard to specificity but also sensitivity, which can be explained by the 
already high performance of RMI in our cohort. The addition of HE4 assessments to 
RMI will not be as tangible as for CA125.  
 
A drawback of HE4 assessments is their increased levels with age and, since EOC 
patients often are elderly women, the detected HE4 level could be confounded by 
age (111, 114, 115). Several groups, have also reported increased serum levels of 
HE4 with increased age, as we found in Paper I and visualized in Paper III. Because 
of this, two research groups modified the ROMA algorithm and incorporated age 
instead of menopausal status, Copenhagen index 1(CPH-1) and ROMA-P (165, 189). 
The ROC AUC, in the study by Karlsen et al., was comparable for RMI, ROMA and 
CPH-1 (0.96, 0.95 and 0.96, respectively), and for the modified ROMA-P compared 
to ROMA (ROC AUC 0.923 and 0.934, respectively). Hence, incorporating age 
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instead of menopausal status did not contribute to an improvement of the predictive 
value of the ROMA algorithm for OC (165, 189). This result was perhaps unexpected 
as the cohorts were taken from a tertiary setting and hosted an elderly cohort 
compared to unselected patients from a normal outpatient clinic, but further 
strengthens that the two cut offs adjusted for menopausal status as used in this thesis 
is sufficient. In fact, when we tested the impact of age in Paper III in our multivariate 
regression model we did not find that age was a predictor associated with false 
positive determinations of HE4 levels, in line with Karlsen et al. (165). This could 
be explained by the fact that age already is taken into account when assessing serum 
levels of HE4, since we use two different cut-off, already adjusting for the 
menopausal status. In fact, when we calculated CPH-1 in the current cohort the 
results were comparable (AUC 0.95) to GOT-I, -II and -III (AUC 0.94-0.95). This 
result indicates that established cut-offs adjusted for menopausal status gives the 
same result as an age-adjusted algorithm. 
 
A similar model named R-OPS (similar to GOT-1) has been proposed by Yanaranop 
et al. (Table 9) (190). Both models achieved similar ROC AUC (0.95) and a higher 
specificity (GOT-1 86% and R-OPS 80%) compared to RMI or ROMA (75% and 
70%, respectively). A difference between our study and that of Yanaranop et al. is 
that the latter used a tertiary center to recruit their patients and, therefore, their EOC 
level was 30%, as compared to 21% in our study. Moreover, all their TVUs were 
performed by an experienced sonographer, which may explain their high sensitivity 
(94%)(190).  These results are, therefore, not applicable to a normal clinical setting, 
where the TVU examiner may be more or less experienced gynecologists, as in our 
multicenter cohort of women.  
 
Several multimarker approaches to improve the diagnostic arsenal to discriminate 
EOC from benign conditions have been reported (Table 9). The Multivariate index 
assay (OVA1) was the first multimarker test to be approved by the FDA in 2009 for 
presurgical risk assessments (170, 191). The OVA1 included analyses of 
Apolipoprotein A-1, transthyretin, beta-2-microglobulin, transferrin (TRF) and 
CA125. It improved the sensitivity compared to assessments by CA125 alone, but 
unfortunately with poor specificity (54%) and consequently a high number of false 
positive cases were reported (170). To improve specificity, Coleman et al. developed 
the second-generation of multivariate index assays, the MIA2G-assay, which 
included assessments of Apolipoprotein A-1, CA125, HE4, follicle stimulating 
hormone (FSH) and TRF, which was approved by the FDA in 2016 (169, 192). This 
assay was better but still doubtful since many false positive cases were reported (SP 
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69%), albeit the sensitivity was excellent (91%) (169). Therefore, we can conclude 
that all three algorithms GOT-1, -2 and -3 performed better than these predecessors 
with a comparable sensitivity, but a much higher specificity (Table 9). Recently 
Moore et al., one of the inventors of the ROMA algorithm, published a multivariate 
analysis model with 8-parameters (chitinase-3-like protein (YKL-40), transthyretin, 
Apolipoprotein A-1, beta-2-microglobulin, transferrin, lysophosphatidic acid (LPA), 
CA125, HE4 and menopausal status), which reached a comparable diagnostic 
accuracy of AUC 0.95 similar to GOT-1 (0.94) (Table 9) (168). Interestingly, they 
found no statistically significant improvement compared to ROMA alone (p-
value=0.078). 
 
These results indicate that adding more parameters, such as multiple protein 
biomarkers, or inventing new expensive assays, is not a cost-effective way forward 
and does not necessarily improve the diagnostic accuracy of the algorithms (193). In 
fact, just combining the well-known biomarkers CA125 and HE4 with TVU 
assessments clearly brings higher sensitivity and specificity to the diagnostic 
assessments of EOC. Thus, our study clearly supports the conclusion that using 
protein biomarkers already validated for EOC in different populations of women, 
perhaps together with TVU, using established cut-off levels for scoring positive 
samples, is the way forward for improved differential diagnosis of an ovarian 
cyst/pelvic tumor of unknown origin. We hope that with increasing knowledge of 
different co-factors impacting on the markers, we have identified the most efficient 
path forward towards improved predictive and accurate differential diagnosis of 
ovarian cancer. 
 
Triage – the impact of different ultrasound assessments   
In this thesis (Papers I-III) both experienced gynecologists and gynecologists under 
training performed the TVU for RMI calculations. The IOTA group has presented 
several different TVU approaches to evaluate pelvic tumors to improve triage and 
referral of patients with suspected cancer to tertiary centers (79, 179, 187, 188). 
Pattern recognition to evaluate tumors based on defined criteria, or the subjective use 
of a risk prediction model, IOTA simple rules, have been proposed as alternatives to 
RMI (194). These models are used to calculate the malignancy risk. The ADNEX 
model was developed to further predict malignancy and the precise type of adnexal 
pathology (195, 196). It should be emphasized that when TVU is performed by an 
experienced sonographer, it often outperforms ROMA and RMI and other algorithms 
(195, 197, 198). For example, the IOTA group reported that RMI (SN 75%; SP 92%) 
was inferior to the logistic regression model 2 (LR2) (SN 93%; SP 84%), and the 
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simple rules (SN 93%; SP 80%) model. This emanated in a recommendation that a 
two-step procedure should be used, based on simple rules, and an assessment (pattern 
recognition) based on observations made by an expert ultrasound examiner (SN 91%; 
SP 91%). Using this approach it was claimed that more patients with malignancies 
would be referred to a tertiary center with specialist ultrasound competence (187). If 
our patients had been assessed according to the IOTA simple rules, our results could 
perhaps be further improved. Simple rules are often referred to as superior to other 
TVU-based algorithms, such as RMI, even in the hands of an unexperienced 
sonographer (199). However, recent data show that the use of simple rules demand 
training and knowledge in both terminology and assessments before implementation, 
which is why it can be questioned whether the performers are correctly classified as 
non-experienced sonographer (200). In a recent publication, 479 patients were 
assessed with TVU by a general gynecologist and it was observed that the IOTA 
analysis (SN 83.8%; SP 92%) was superior to the RMI algorithm (SN 77.2%; SP 
86,8%), but as many as 18% of the assessments using IOTA simple rules were 
inconclusive and needed expert evaluations (201). 
 
Access to an expert sonographer is limited in a general clinical setting (202). 
Moreover, since RMI includes serum levels of CA125 only, while ROMA with the 
addition of HE4 is more adequate and reliable, especially in patients that are 
premenopausal.  Hence, the ROMA algorithm, based on measurable parameters only, 
is advantageous to use as a first line diagnostic assessment as it does not rely on 
specialists for the clinical assessment or TVU. 
 
When using biomarkers, should we suspect that lifestyle factors or comorbidity 
will impact on their diagnostic value?   
The results in Paper I and II clearly show that the addition of HE4 determinations in 
serum adds to the diagnostic arsenal and allows us to discriminate better between 
benign and malignant conditions, especially in the premenopausal group. Several 
factors have been proposed to impact on the interpretation of HE4 levels, such as 
smoking, age, renal failure, hormonal treatment, pregnancy, menstrual cycle, BMI, 
heart failure and analysis with different platforms (111-115, 120, 125, 176, 203, 204). 
The strength of our study (Paper I-III) is the clinical setting, the large cohort of 
women and that we used recommended cut-offs. In this thesis we additionally aimed 
at investigate different predictors associated with a false negative outcome when 
truly malignant tumors were eventually diagnosed. In fact, it is particularly 
noteworthy that in our study the false negative cases were few; with 10 cases for 
CA125 and 35 for HE4 assessments. No results were obtained for the sub-analyses 
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of false negative CA125 values, due to the few cases detected. On the other hand, we 
looked more carefully into the false negative group of HE4 determinations. In our 
cohort, assessments of HE4 was unable to detect malignancies of mucinous 
histology, indicated by both the serum levels of HE4 (Table 7) and the multivariate 
regression model. These results are in line with prior knowledge of HE4 inability to 
detect mucinous carcinoma (86, 110).  
 
On the other hand high levels of false positive CA125 assessments can be expected 
(31%), especially in the group of premenopausal women (40%). This finding 
confirms prior observations claiming that CA125 assessments have several 
drawbacks. The results further support that the combination with HE4 assessments 
has clear advantages as a diagnostic marker in the premenopausal group. As 
aforementioned, both biomarkers can be expected to be elevated in several benign 
conditions or found elevated with other malignancies, not just for EOC (205). It is 
mandatory that the examiner penetrates the patients’ medical and gynecologic 
history, including smoking habits, renal failure, endometriosis, as well as age, when 
analyzing serum levels of HE4 and CA125 as showed in Paper III (103, 111-115, 
120, 176, 203, 204, 206). Thus, the patient history is a critical component and should 
be acknowledged accordingly in a comprehensive diagnostic effort to discriminate 
benign from malignant tumors in the pelvis of women. 
 
EOC – is a heterogenous group of ovarian cancers     
Today it has become increasingly clear that EOC is not one disease, but rather 
includes highly heterogenous diseases with different origins as well as mutations that 
characterize them (129, 207). The histopathologic classification of EOC and how we 
can integrate molecular genetic features with morphology are going to have a strong 
impact on the diagnostics and treatments of EOC and cancer in general. The dualistic 
model takes into account histopathological classifications and integrates genetic 
findings, which have provided a path to the future where molecular and 
morphological pathogenesis interact (27). For example, the integration of precise 
mutations in the different subtypes have become cornerstones in the improvement of 
the diagnostic arsenal for EOC, with separate origin, aggressivity and prognosis. 
These observations address the urgent need for pin-pointed diagnostic markers. EOC 
analysis using high-throughput next generation sequencing (NGS) techniques has 
positively impacted our ability to determine EOC and subgroup the malignant 
conditions, as we can better separate them from benign conditions. The TCGA 
library of selected genomic alterations at the DNA, RNA, epigenetic and protein 
levels has become the basis for several trials, using NGS techniques in the 
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assessments of EOC and HGSC (10). A common denominator in these novel 
approaches is the liquid biopsy, which allows us to search for tumor cells or DNA.  
In addition, some EOC relevant protein biomarkers, such as serum CA125 and HE4, 
have been identified and evaluated in this thesis, for an improved diagnostic arsenal 
for EOC assessments.  In the future, several different approaches for detection and 
possibly screening using molecular techniques will be available. These are now being 
evaluated in both discovery and analytical validation trials, but it will take time 
before they can be clinically implemented (208-210). However, already today we can 
conclude that mutations identified, with ctDNA in plasma increased the sensitivity 
of the analysis as compared to a PapSEEK/Pap brush (cervical biopsy) analysis alone 
from 33% to 63%. This is quite a remarkable finding, but it should be noted that a 
drawback of ctDNA assessments is the natural introduction of mutations due to aging 
that are not associated with cancers. Hence, ctDNA mutations do not necessarily 
have to imply cancer. In Paper IV we attempted to separate these two elements to 
adjust for ageing. We compared the actual mutations found in the cancer specimens 
and the mutations found in the liquid biopsies. We found that 97% of the endometrial 
tumors had at least one mutation in both the brush samples (Pap brush and TAO 
brush) as well as in the primary tumor. For the ovarian tumors, on the other hand, 
73% and 53% had the same detectable mutations in primary tumors as for Pap- and 
TAO brush samples, respectively. The results were promising, but still 
improvements of this diagnostic tool need to be added before we can rely on them in 
the clinical practice for an accurate diagnosis of ovarian malignancies. The results 
for the ovarian tumors could be explained and further support the knowledge of 
tumor heterogeneity, since only a small proportion of the tumor was sampled and 
sequenced (211). 
 
Can screening for EOC ever become a preventive step to reduce the number of 
cases in the future?   
It is exciting to consider that a future possibility could be to introduce screening 
programs for ovarian cancer in conjunction with the existing national cervical 
screening program. In fact, several attempts to screen for ovarian cancer have already 
been done, but the outcome of these have been discouraging, and presently it is not 
recommended (212-214). This is because of the high level of false positive results 
when using the established diagnostic tools and the lack of data supporting an 
increase in ovarian cancer survival in screening programs (215). It must be 
emphasized that ovarian cancer is often diagnosed in an advanced stage of disease, 
because it can be completely asymptomatic initially. However, in the future more 
accurate diagnostic tools such as genetic markers for ovarian cancers, and screening 
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programs as for cervical- breast- and colon cancer, may be introduced. In Paper IV 
we evaluated such a genetic approach for diagnosing ovarian cancer using two 
different non-invasive techniques to screen for gynecological cancer in a non-high-
risk population. If the PapSEEK analysis can be used as a diagnostic test, it should 
perform better than e.g. assessments of CA125 in serum (Paper I). Unfortunately, the 
sensitivity of PapSEEK was low; 33% for Pap brush samples and 45% for TAO-
brush samples. CA125 assessments in serum had a much better predictive value in 
this thesis; sensitivity of 95.7% (CA125 Pre-M), and 92% (CA125 Post-M), in Paper 
I. At present CA125 assessments carry a much better value as a diagnostic marker 
for detecting ovarian malignant disease compared to the PapSEEK analysis after Pap 
brush and TAO brush sample collection. An overriding problem with established 
diagnostic tools for EOC is that their sensitivity may be high, but the specificity is 
often rather low. With these genetic markers the opposite was found and the 
specificity of the PapSEEK analysis was close to 100% for both Pap-and TAO brush 
samples, compared to 59.6% (Pre-M) and 79.5% (Post-M) for assessments of CA125 
(Paper I). HE4 assessments, on the other hand, reached higher sensitivity (Pre-M 
82.6%; Post-M 72.3%) and close to the specificity of the PapSEEK analysis (HE4 
Pre-M 90.9%; HE4 Post-M 92.1%). In Paper IV a subgroup analysis was conducted 
to test if the sensitivity could be improved. Detection of specific mutations in ctDNA 
found in plasma and from Pap brush samples identified an improved sensitivity of 
63%, when scoring one of the two tests as a positive sample. These results are 
interesting for the future, but still the sensitivity is too low to recommend this 
approach as a screening tool for ovarian cancer.   
 
One general problem can be that advanced cases of ovarian cancer may have 
anatomical changes that can prevent shedding of cancer cells. Detection of tumor 
DNA in the uterine cavity or cervix upon local sampling may also be difficult. In 
addition, another problem may be women with prior tubal ligation or salpingectomy. 
Several other methods have been evaluated such as vaginal self-swabs, tampons or 
uterine lavage, unfortunately with little success and insufficient predictive values for 
general screening (216, 217). Two large randomized controlled trials (RCT) have 
been conducted with the aim to screen for ovarian cancer: the UK collaborative Trial 
of Ovarian Cancer Screening (UKTOCS) trial (n=202,546) and the Prostate, Lung, 
colorectal and Ovarian (PLCO) trial (n=68,447). In addition, the Kentucky cancer 
screening program has evaluated almost 40,000 American women with annual 
screening with TVU in a population/control study. They have reported increased 
specificity and PPV of 20-24.7%, which means that over time using this annual 
investigation method only 3 or 4 women with a benign diagnosis will go through 
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surgery to find one cancer (66, 218, 219). The UKTOCS trial had two intervention 
arms. The first arm was a multimodal screening (MMS) strategy, in which the women 
went through CA125 assessments annually and the follow-up was determined by the 
risk of ovarian cancer algorithm (ROCA) to either CA125 assessment after 6 weeks, 
3 months, or TVU assessments according to the risk calculation of the algorithm 
(220). It should be noted that ROCA calculates a statistical risk of OC from serial 
measurement of serum levels of CA125 rather than from a single sample cut-off level 
(167, 221). The second intervention arm included annual TVU and a control group 
with no screening. However, neither of these screening models were successful, as 
0.34% of the women tested in the control group died in OC, while 0.29% in the MMS 
arm and 0.30% in the TVU arm died in OC (p-value = 0.23) (212). The screening 
also revealed that 44% in the MMS arm had at least one false positive result, and 
accordingly general screening was not recommended (222). A similar observation 
was done in the PLCO trial of women in which CA125 testing and TVU was 
performed annually in the intervention arm. The relative frequency of death in OC 
was similar to that of the control group that did not undergo any screening (0.31% 
intervention arm; 0.29% control arm) (212, 213). Of note, the complication rate for 
the women who underwent surgery was 15% higher in women with benign diagnose 
as compared to the UKTOCS trial, in which 3.1-3.5% complication rate was 
reported. Thus, screening for ovarian cancer has not been successful and the 
consensus today is that screening for ovarian cancer in the general population of 
women should not be recommended (215). Screening in high risk populations for 
ovarian cancer is conducted in the US with annual TVU and CA125, but not 
recommended in the UK, as it apparently does not detect early stage cancers (222, 
223). Current guidelines in Sweden do not recommend annual screening for ovarian 
cancer with TVU and/or CA125 assessments. 
 
Are there other approaches for liquid biopsies sampling?   
Due to the anatomy of the female reproductive tract, EOC afflicted tissues, cells or 
DNA may be difficult to sample. As symptoms often are subclinical, patients come 
to the medical attention at a late stage of disease. However, circulating tumor cells 
(CTCs) contribute to the metastatic process and shedding of tumor cfDNA or ctDNA 
into the blood circulation is most likely to occur at an advanced stage of disease. 
Detection of CTCs in the bloodstream in early stage cancer has been disappointing 
with low sensitivity for different types of primary cancers including ovarian. 
Therefore, hope has been given to ctDNA detection as a means to analyze small 
amounts of materials from an ovarian cancer. Even a small fraction of ctDNA can 
undergo extensive analysis, which implies a revolution of high-throughput 
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techniques and allows a better understanding of cancer biology. Liquid biopsies are 
non-invasive, inexpensive and tolerable for most women, but not as sensitive when 
sampled from blood as when taken from the genital tract closer to the primary tumors. 
Hence, samplings from the peritoneal fluid, uterine lavage, cyst fluid or tampons 
have been evaluated (217, 224, 225). Sampling with Pap- and TAO brush from the 
cervix and the endometrial lining of the uterine cavity was used in Paper IV, as an 
alternative to liquid biopsies in blood for improved early diagnostics and as potential 
screening source. Yet another source of sampling is the direct sampling from ovarian 
cyst fluid, and in an earlier study we could demonstrate that such fluid contained high 
level of proteins, monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 
(IL-8) levels that were increased in borderline and early stage malignant cysts 
compared to benign cysts. Thus, malignant disease could indirectly be spotted by 
enhanced inflammatory markers in the ovarian cyst fluid and detected early in the 
disease (226). The same authors observed that ovarian cyst fluid harbored other 
potential biomarkers for EOC such as Apolipoprotein C-III. This biomarker was 
significantly increased in malignant ovarian cysts compared to benign (p=0.001), and 
could be used for early detection of ovarian cancer. Together with prof Vogelstein´s 
group in Baltimore, ovarian cyst fluids were analyzed and found to include tumor 
specific mutations, 100% concordant, with the mutations found in corresponding 
primary EOC (225). The tumor-specific mutations were detectable in 83% in 
borderline type tumors, 77% of type I and 100% type II tumors (225). Intraabdominal 
fine needle aspiration of ovarian cysts for detection of malignancy, is not 
recommended. A puncture of the cyst for cytology or liquid biopsy gene sequencing 
before surgery might cause leakage of tumor cells, increased risk of metastasis and 
upstaging of the disease. As of yet, no groundbreaking solution of how to perform 
preoperative diagnostic sampling of ovarian cysts in situ has been put forward. 
Punction in an already metastasized disease is on the contrary not contraindicated, 
but recommended for the decision of treatment.  
  
Whereas the present sampling techniques are yet to be refined ongoing work is 
clearly pointing to that early diagnosis of ovarian cancer can be achieved with liquid 
biopsies in the future. Screening for specific mutations has already shown improved 
specificity in diagnosing ovarian cancers, although sensitivity is still an imminent 
problem. Detection of tumor DNA in a thin prep fluid sample is a brilliant idea, but 
the approach still needs to be improved. The diagnostic accuracy was higher for 
endometrial cancer than for ovarian cancers. This is not unexpected, as access to 
ovarian tissue is limited at this location and a large proportion of patients enrolled in 
the study were suffering from advanced disease, often with obliterated fallopian 
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tubes, which easily explains the discrepant results when comparing endometrial and 
ovarian cancer diagnosis using this technique. Additionally, for the 18 and 16 genes 
respectively assessed in Paper IV, mutations were more specific for endometrial 
cancer and several important ovarian cancer mutations such as ARID1A and 
BRCA1/2 were not assessed (table 2). We believe that a larger and prospective trial 
needs to be undertaken to better evaluate the benefits of the PapSEEK method for 
early diagnosis of ovarian cancers. Additionally, including the combination of 
analysis of protein biomarkers and a healthy control group would be of interest in the 
future. It may still be early days of the liquid biopsy approach to acquire predictive 
tools for ovarian cancer diagnosis. However, our work in Paper IV hold promise and 
clearly identifies a way forward. 
 
One treatment does not fit all   
Diagnostic tools with high specificity and sensitivity have been lacking for 
assessment of ovarian cancer. With the much-improved knowledge about the 
molecular mechanisms and different oncogenetic features in EOC, the origin of EOC 
have to be considered. Thus, today we know that EOC is as a group of heterogeneous 
cancers, which partly explains why generalized treatment is hard to achieve. There 
are at least two key factors that may improve survival of women diagnosed with 
EOC: 1) screening for EOC and 2) individualized treatment. Identifying different 
biomarkers is another example of a future strategic development for improving early 
diagnosis, which also could take into account histological staging of the different 
cancer subtypes. This approach can hopefully improve the predictive value of a 
diagnostic test and suggest better personalized treatments. There are a few good 
examples. Adjuvant treatment with anti-VEGF antibody (bevacizumab) in 
combination with a platinum-based chemotherapy increases progression free 
survival (PFS), but not overall survival (OS), in advanced ovarian cancer. A 
drawback with this strategy is the lack of molecular markers that could be used to 
diagnose who would benefit from a particular treatment. Another encouraging 
example is EOC patients with BRCA mutations. When treated with poly ADP ribose 
polymerase- (PARP) inhibitors, they have exhibited prolonged PFS. This holds 
promise for future development of better diagnostic tools (227, 228). The high 
amount of TP53 mutations in HGSC makes targeted treatment against TP53 
mutations attractive (10). There are ongoing phase II trials, and hopefully a TP53-
targeted treatment can be implemented in clinical routine in the future (229).   
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Conclusion 
 
 
 At the recommended cut-off level of >35, assessments of CA125 out-
performed serum levels of HE4 in diagnosing EOC, but as many as 40% of 
the women with benign disease in the cohort had false positive CA125 levels. 
On the other hand, assessments of HE4, using recommended cut-off levels 
outperformed CA125 in identifying the benign cases and, hence, helps 
reducing the false positive results (Paper I). 
 
 The diagnostic ability of the algorithms RMI and ROMA was comparable in 
this cohort using the recommended cut-off levels, supporting that the ROMA 
algorithm can be used as a first line triage tool, since it does not rely on a 
specialist for ultrasound assessments (Paper I). 
 
 Combining assessments of HE4 in serum with CA125 determinations or with 
RMI significantly improved the specificity for diagnosing ovarian cancer. In 
addition, adding TVU analysis to the ROMA algorithm improved specificity 
for EOC in both pre- and postmenopausal women as compared to routine 
diagnostic assessments (the baseline models) (Paper II). 
 
 It is important to penetrate the medical and gynecological history and 
acknowledge factors such as age, smoking habits, presence of heart disease, 
renal failure, and microscopy-verified endometriosis before concluding the 
relevance of increased serum levels of HE4 or CA125 in patients with a 
suspected ovarian cyst/pelvic tumor (Paper III). 
 
 Serum levels of HE4 should be included in clinical investigations of a 
suspected ovarian cyst/pelvic tumor in pre-menopausal women. 
 
 The new diagnostic possibilities that come with liquid biopsies and high 
throughput molecular analysis of gene mutations have improved the 
specificity of EOC diagnosis and allowed us to effectively discriminate 
between benign conditions and malignant tumors (Paper IV).  
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 Sampling of DNA from cervical or endometrial liquid biopsies has made rare 
mutation detection simple and when combined with detection of ctDNA 
sensitivity can be increased without hampering specificity (paper IV). 
 
 This thesis demonstrates that if we combine the right parameters we can 
significantly improve the prognostic value of the EOC-diagnosis and it may 
help us to identify malignant disease at an early stage and improve differential 
diagnosis.  
 
 High-throughput molecular analyses has given us an increased understanding 
of the etiology of EOC and hopefully this will lead to more specific diagnostic 
tests and individualized therapies.  
 
 It can be foreseen that clinical implementation of the new diagnostic tools may 
take time, but we should be more optimistic today as we have seen promising 
new developments. 
 
 Even though new molecular genetics holds promise, we still can explore the 
use of biomarkers, such as serum levels of CA125 and HE4. If combined with 
an algorithm, such as RMI, these assessments could have immediate clinical 
implications for improving the accuracy of EOC diagnosis. 
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